Abstract
Cancers must alter their metabolism to satisfy the increased demand for energy and to produce building blocks that are required to create a rapidly growing tumor. Further, for cancer cells to thrive, they must also adapt to an often changing tumor microenvironment, which can present new metabolic challenges (ex. hypoxia) that are unfavorable for most other cells. As such, altered metabolism is now considered an emerging hallmark of cancer. Like many other malignancies, the metabolism of prostate cancer is considerably different compared to matched benign tissue. However, prostate cancers exhibit distinct metabolic characteristics that set them apart from many other tumor types. In this chapter, we will describe the known alterations in prostate cancer metabolism that occur during initial tumorigenesis and throughout disease progression. In addition, we will highlight upstream regulators that control these metabolic changes. Finally, we will discuss how this new knowledge is being leveraged to improve patient care through the development of novel biomarkers and metabolically targeted therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
O. Warburg, On the origin of cancer cells. Science 123(3191), 309–314 (1956). https://doi.org/10.1126/science.123.3191.309
O. Warburg, F. Wind, E. Negelein, The metabolism of tumors in the body. J. Gen. Physiol. 8(6), 519–530 (1927). https://doi.org/10.1085/jgp.8.6.519
D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011). https://doi.org/10.1016/j.cell.2011.02.013
L.C. Costello, R.B. Franklin, A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch. Biochem. Biophys. 611, 100–112 (2016). https://doi.org/10.1016/j.abb.2016.04.014
L.C. Costello, R.B. Franklin, P. Feng, Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5(3), 143–153 (2005). https://doi.org/10.1016/j.mito.2005.02.001
L.C. Costello, R.B. Franklin, Zinc is decreased in prostate cancer: an established relationship of prostate cancer. J. Biol. Inorg. Chem. 16(1), 3–8 (2011). https://doi.org/10.1007/s00775-010-0736-9
L.C. Costello, R.B. Franklin, Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate. Enzyme 26(6), 281–287 (1981). https://doi.org/10.1159/000459195
L.C. Costello, R.B. Franklin, Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 35(4), 285–296 (1998). https://doi.org/10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F
L.C. Costello, R.B. Franklin, The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer 5, 17 (2006). https://doi.org/10.1186/1476-4598-5-17
L.C. Costello, Y. Liu, R.B. Franklin, M.C. Kennedy, Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J. Biol. Chem. 272(46), 28875–28881 (1997). https://doi.org/10.1074/jbc.272.46.28875
M.M. Desouki, J. Geradts, B. Milon, R.B. Franklin, L.C. Costello, hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. Mol. Cancer 6, 37 (2007). https://doi.org/10.1186/1476-4598-6-37
R.B. Franklin, P. Feng, B. Milon, M.M. Desouki, K.K. Singh, A. Kajdacsy-Balla, O. Bagasra, L.C. Costello, hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer 4, 32 (2005). https://doi.org/10.1186/1476-4598-4-32
M.C. Franz, P. Anderle, M. Burzle, Y. Suzuki, M.R. Freeman, M.A. Hediger, G. Kovacs, Zinc transporters in prostate cancer. Mol. Aspects Med. 34(2-3), 735–741 (2013). https://doi.org/10.1016/j.mam.2012.11.007
E. Eidelman, J. Twum-Ampofo, J. Ansari, M.M. Siddiqui, The metabolic phenotype of prostate cancer. Front. Oncol. 7, 131 (2017). https://doi.org/10.3389/fonc.2017.00131
P. Feng, J.Y. Liang, T.L. Li, Z.X. Guan, J. Zou, R. Franklin, L.C. Costello, Zinc induces mitochondria apoptogenesis in prostate cells. Mol. Urol. 4(1), 31–36 (2000)
P. Feng, T.L. Li, Z.X. Guan, R.B. Franklin, L.C. Costello, Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 52(4), 311–318 (2002). https://doi.org/10.1002/pros.10128
R.B. Franklin, L.C. Costello, Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch. Biochem. Biophys. 463(2), 211–217 (2007). https://doi.org/10.1016/j.abb.2007.02.033
F. Cutruzzola, G. Giardina, M. Marani, A. Macone, A. Paiardini, S. Rinaldo, A. Paone, Glucose metabolism in the progression of prostate cancer. Front. Physiol. 8, 97 (2017). https://doi.org/10.3389/fphys.2017.00097
I. Rishi, H. Baidouri, J.A. Abbasi, R. Bullard-Dillard, A. Kajdacsy-Balla, J.P. Pestaner, M. Skacel, R. Tubbs, O. Bagasra, Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl. Immunohistochem. Mol. Morphol. 11(3), 253–260 (2003)
P.B. Makhov, K.V. Golovine, A. Kutikov, D.J. Canter, V.A. Rybko, D.A. Roshchin, V.B. Matveev, R.G. Uzzo, V.M. Kolenko, Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis 32(12), 1773–1781 (2011). https://doi.org/10.1093/carcin/bgr212
L. Latonen, E. Afyounian, A. Jylha, J. Nattinen, U. Aapola, M. Annala, K.K. Kivinummi, T.T.L. Tammela, R.W. Beuerman, H. Uusitalo, M. Nykter, T. Visakorpi, Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat. Commun. 9(1), 1176 (2018). https://doi.org/10.1038/s41467-018-03573-6
K. Naruse, Y. Yamada, S. Aoki, T. Taki, K. Nakamura, M. Tobiume, K. Zennami, R. Katsuda, S. Sai, Y. Nishio, Y. Inoue, H. Noguchi, N. Hondai, Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo 53(5), 287–292 (2007)
I. Elia, R. Schmieder, S. Christen, S.M. Fendt, Organ-specific cancer metabolism and its potential for therapy. Handb. Exp. Pharmacol. 233, 321–353 (2016). https://doi.org/10.1007/164_2015_10
J. Wang, J. Li, X. Li, S. Peng, J. Li, W. Yan, Y. Cui, H. Xiao, X. Wen, Increased expression of glycolytic enzymes in prostate cancer tissues and association with Gleason score. Int. J. Clin. Exp. Pathol. 10(11), 11080–11089 (2017)
H. Xiao, J. Wang, W. Yan, Y. Cui, Z. Chen, X. Gao, X. Wen, J. Chen, GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate 78(2), 86–94 (2018). https://doi.org/10.1002/pros.23448
J. Jans, J.H. van Dijk, S. van Schelven, P. van der Groep, S.H. Willems, T.N. Jonges, P.J. van Diest, J.L. Bosch, Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75(4), 786–792 (2010). https://doi.org/10.1016/j.urology.2009.08.024
C.V. Vaz, M.G. Alves, R. Marques, P.I. Moreira, P.F. Oliveira, C.J. Maia, S. Socorro, Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int. J. Biochem. Cell Biol. 44(11), 2077–2084 (2012). https://doi.org/10.1016/j.biocel.2012.08.013
P. Gonzalez-Menendez, D. Hevia, R. Alonso-Arias, A. Alvarez-Artime, A. Rodriguez-Garcia, S. Kinet, I. Gonzalez-Pola, N. Taylor, J.C. Mayo, R.M. Sainz, GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol. 17, 112–127 (2018). https://doi.org/10.1016/j.redox.2018.03.017
M.A. White, E. Tsouko, C. Lin, K. Rajapakshe, J.M. Spencer, S.R. Wilkenfeld, S.S. Vakili, T.L. Pulliam, D. Awad, F. Nikolos, R.R. Katreddy, B.A. Kaipparettu, A. Sreekumar, X. Zhang, E. Cheung, C. Coarfa, D.E. Frigo, GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr. Relat. Cancer 25(4), 453–469 (2018). https://doi.org/10.1530/ERC-17-0051
P. Gonzalez-Menendez, D. Hevia, J.C. Mayo, R.M. Sainz, The dark side of glucose transporters in prostate cancer: are they a new feature to characterize carcinomas? Int. J. Cancer 142(12), 2414–2424 (2018). https://doi.org/10.1002/ijc.31165
N. Pertega-Gomes, S. Felisbino, C.E. Massie, J.R. Vizcaino, R. Coelho, C. Sandi, S. Simoes-Sousa, S. Jurmeister, A. Ramos-Montoya, M. Asim, M. Tran, E. Oliveira, A. Lobo da Cunha, V. Maximo, F. Baltazar, D.E. Neal, L.G. Fryer, A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J. Pathol. 236(4), 517–530 (2015). https://doi.org/10.1002/path.4547
Y. Deng, J. Lu, Targeting hexokinase 2 in castration-resistant prostate cancer. Mol. Cell. Oncol. 2(3), e974465 (2015). https://doi.org/10.4161/23723556.2014.974465
L. Wang, H. Xiong, F. Wu, Y. Zhang, J. Wang, L. Zhao, X. Guo, L.J. Chang, Y. Zhang, M.J. You, S. Koochekpour, M. Saleem, H. Huang, J. Lu, Y. Deng, Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 8(5), 1461–1474 (2014). https://doi.org/10.1016/j.celrep.2014.07.053
P. Zhou, W.G. Chen, X.W. Li, MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. Am. J. Cancer Res. 5(6), 2056–2063 (2015)
P.L. Martin, J.J. Yin, V. Seng, O. Casey, E. Corey, C. Morrissey, R.M. Simpson, K. Kelly, Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene 36(4), 525–533 (2017). https://doi.org/10.1038/onc.2016.223
T. Tao, M. Chen, R. Jiang, H. Guan, Y. Huang, H. Su, Q. Hu, X. Han, J. Xiao, Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis. Oncol. Rep. 37(3), 1430–1436 (2017). https://doi.org/10.3892/or.2017.5430
J.S. Moon, W.J. Jin, J.H. Kwak, H.J. Kim, M.J. Yun, J.W. Kim, S.W. Park, K.S. Kim, Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem. J. 433(1), 225–233 (2011). https://doi.org/10.1042/BJ20101104
K.C. Patra, Q. Wang, P.T. Bhaskar, L. Miller, Z. Wang, W. Wheaton, N. Chandel, M. Laakso, W.J. Muller, E.L. Allen, A.K. Jha, G.A. Smolen, M.F. Clasquin, B. Robey, N. Hay, Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2), 213–228 (2013). https://doi.org/10.1016/j.ccr.2013.06.014
P.W. Stacpoole, Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J. Natl. Cancer Inst. 109(11) (2017). https://doi.org/10.1093/jnci/djx071
E. Kolobova, A. Tuganova, I. Boulatnikov, K.M. Popov, Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem. J. 358(1), 69–77 (2001). https://doi.org/10.1042/bj3580069
G. Sutendra, E.D. Michelakis, Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front. Oncol. 3, 38 (2013). https://doi.org/10.3389/fonc.2013.00038
Y. Zhong, X. Li, Y. Ji, X. Li, Y. Li, D. Yu, Y. Yuan, J. Liu, H. Li, M. Zhang, Z. Ji, D. Fan, J. Wen, M.A. Goscinski, L. Yuan, B. Hao, J.M. Nesland, Z. Suo, Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers. Oncotarget 8(8), 13344–13356 (2017). https://doi.org/10.18632/oncotarget.14527
J. Chen, I. Guccini, D. Di Mitri, D. Brina, A. Revandkar, M. Sarti, E. Pasquini, A. Alajati, S. Pinton, M. Losa, G. Civenni, C.V. Catapano, J. Sgrignani, A. Cavalli, R. D’Antuono, J.M. Asara, A. Morandi, P. Chiarugi, S. Crotti, M. Agostini, M. Montopoli, I. Masgras, A. Rasola, R. Garcia-Escudero, N. Delaleu, A. Rinaldi, F. Bertoni, J. Bono, A. Carracedo, A. Alimonti, Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat. Genet. 50(2), 219–228 (2018). https://doi.org/10.1038/s41588-017-0026-3
G. Sutendra, A. Kinnaird, P. Dromparis, R. Paulin, T.H. Stenson, A. Haromy, K. Hashimoto, N. Zhang, E. Flaim, E.D. Michelakis, A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 158(1), 84–97 (2014). https://doi.org/10.1016/j.cell.2014.04.046
M.C. Hsu, W.C. Hung, Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling. Mol. Cancer 17(1), 35 (2018). https://doi.org/10.1186/s12943-018-0791-3
F.A. Siddiqui, G. Prakasam, S. Chattopadhyay, A.U. Rehman, R.A. Padder, M.A. Ansari, R. Irshad, K. Mangalhara, R.N.K. Bamezai, M. Husain, S.M. Ali, M.A. Iqbal, Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1alpha inhibition. Sci. Rep. 8(1), 8323 (2018). https://doi.org/10.1038/s41598-018-25524-3
N. Wong, J. Yan, D. Ojo, J. De Melo, J.C. Cutz, D. Tang, Changes in PKM2 associate with prostate cancer progression. Cancer Invest. 32(7), 330–338 (2014). https://doi.org/10.3109/07357907.2014.919306
G. Dong, Q. Mao, W. Xia, Y. Xu, J. Wang, L. Xu, F. Jiang, PKM2 and cancer: the function of PKM2 beyond glycolysis. Oncol. Lett. 11(3), 1980–1986 (2016). https://doi.org/10.3892/ol.2016.4168
H.J. Wang, M. Pochampalli, L.Y. Wang, J.X. Zou, P.S. Li, S.C. Hsu, B.J. Wang, S.H. Huang, P. Yang, J.C. Yang, C.Y. Chu, C.L. Hsieh, S.Y. Sung, C.F. Li, C.G. Tepper, D.K. Ann, A.C. Gao, C.P. Evans, Y. Izumiya, C.P. Chuu, W.C. Wang, H.W. Chen, H.J. Kung, KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene 38, 17 (2019). https://doi.org/10.1038/s41388-018-0414-x
Y. Yasumizu, H. Hongo, T. Kosaka, S. Mikami, K. Nishimoto, E. Kikuchi, M. Oya, PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. Oncotarget 9(45), 27698–27707 (2018). https://doi.org/10.18632/oncotarget.25498
D. Hasan, E. Gamen, N. Abu Tarboush, Y. Ismail, O. Pak, B. Azab, PKM2 and HIF-1alpha regulation in prostate cancer cell lines. PLoS One 13(9), e0203745 (2018). https://doi.org/10.1371/journal.pone.0203745
E. Giannoni, M.L. Taddei, A. Morandi, G. Comito, M. Calvani, F. Bianchini, B. Richichi, G. Raugei, N. Wong, D. Tang, P. Chiarugi, Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget 6(27), 24061–24074 (2015). https://doi.org/10.18632/oncotarget.4448
Z.Y. Xian, J.M. Liu, Q.K. Chen, H.Z. Chen, C.J. Ye, J. Xue, H.Q. Yang, J.L. Li, X.F. Liu, S.J. Kuang, Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biol. 36(10), 8093–8100 (2015). https://doi.org/10.1007/s13277-015-3540-x
M.I. Koukourakis, A. Giatromanolaki, M. Panteliadou, S.E. Pouliliou, P.S. Chondrou, S. Mavropoulou, E. Sivridis, Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br. J. Cancer 110(9), 2217–2223 (2014). https://doi.org/10.1038/bjc.2014.158
S.Y. Choi, H. Xue, R. Wu, L. Fazli, D. Lin, C.C. Collins, M.E. Gleave, P.W. Gout, Y. Wang, The MCT4 gene: a novel, potential target for therapy of advanced prostate cancer. Clin. Cancer Res. 22(11), 2721–2733 (2016). https://doi.org/10.1158/1078-0432.CCR-15-1624
J.R. Doherty, J.L. Cleveland, Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123(9), 3685–3692 (2013). https://doi.org/10.1172/JCI69741
J. Liu, G. Chen, Z. Liu, S. Liu, Z. Cai, P. You, Y. Ke, L. Lai, Y. Huang, H. Gao, L. Zhao, H. Pelicano, P. Huang, W.L. McKeehan, C.L. Wu, C. Wang, W. Zhong, F. Wang, Aberrant FGFR tyrosine kinase signaling enhances the warburg effect by reprogramming LDH isoform expression and activity in prostate cancer. Cancer Res. 78(16), 4459–4470 (2018). https://doi.org/10.1158/0008-5472.CAN-17-3226
R.S. Jones, M.E. Morris, Monocarboxylate transporters: therapeutic targets and prognostic factors in disease. Clin. Pharmacol. Ther. 100(5), 454–463 (2016). https://doi.org/10.1002/cpt.418
M.C. Wilson, V.N. Jackson, C. Heddle, N.T. Price, H. Pilegaard, C. Juel, A. Bonen, I. Montgomery, O.F. Hutter, A.P. Halestrap, Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. J. Biol. Chem. 273(26), 15920–15926 (1998). https://doi.org/10.1074/jbc.273.26.15920
S.Y.C. Choi, S.L. Ettinger, D. Lin, H. Xue, X. Ci, N. Nabavi, R.H. Bell, F. Mo, P.W. Gout, N.E. Fleshner, M.E. Gleave, C.C. Collins, Y. Wang, Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med. 7, 3385 (2018). https://doi.org/10.1002/cam4.1587
N. Pertega-Gomes, J.R. Vizcaino, V. Miranda-Goncalves, C. Pinheiro, J. Silva, H. Pereira, P. Monteiro, R.M. Henrique, R.M. Reis, C. Lopes, F. Baltazar, Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11, 312 (2011). https://doi.org/10.1186/1471-2407-11-312
P. Sanita, M. Capulli, A. Teti, G.P. Galatioto, C. Vicentini, P. Chiarugi, M. Bologna, A. Angelucci, Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer 14, 154 (2014). https://doi.org/10.1186/1471-2407-14-154
N. Pertega-Gomes, J.R. Vizcaino, S. Felisbino, A.Y. Warren, G. Shaw, J. Kay, H. Whitaker, A.G. Lynch, L. Fryer, D.E. Neal, C.E. Massie, Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget 6(25), 21675–21684 (2015). https://doi.org/10.18632/oncotarget.4328
I. Valenca, N. Pertega-Gomes, J.R. Vizcaino, R.M. Henrique, C. Lopes, F. Baltazar, D. Ribeiro, Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J. Cell. Mol. Med. 19(4), 723–733 (2015). https://doi.org/10.1111/jcmm.12481
H.S. Kim, E.M. Masko, S.L. Poulton, K.M. Kennedy, S.V. Pizzo, M.W. Dewhirst, S.J. Freedland, Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 110(7), 1062–1069 (2012). https://doi.org/10.1111/j.1464-410X.2012.10971.x
P. Jiang, W. Du, M. Wu, Regulation of the pentose phosphate pathway in cancer. Protein Cell 5(8), 592–602 (2014). https://doi.org/10.1007/s13238-014-0082-8
E.S. Cho, Y.H. Cha, H.S. Kim, N.H. Kim, J.I. Yook, The pentose phosphate pathway as a potential target for cancer therapy. Biomol. Ther. 26(1), 29–38 (2018). https://doi.org/10.4062/biomolther.2017.179
I.A. da Costa, J. Hennenlotter, V. Stuhler, U. Kuhs, M. Scharpf, T. Todenhofer, A. Stenzl, J. Bedke, Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. Urol. Oncol. 36(10), 472.e421–472.e427 (2018). https://doi.org/10.1016/j.urolonc.2018.06.010
E. Tsouko, A.S. Khan, M.A. White, J.J. Han, Y. Shi, F.A. Merchant, M.A. Sharpe, L. Xin, D.E. Frigo, Regulation of the pentose phosphate pathway by an AR-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 3, e103 (2014). https://doi.org/10.1038/oncsis.2014.18
M. Ookhtens, R. Kannan, I. Lyon, N. Baker, Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. Regul. Integr. Compar. Physiol. 247(1), R146–R153 (1984). https://doi.org/10.1152/ajpregu.1984.247.1.R146
W. Han, S. Gao, D. Barrett, M. Ahmed, D. Han, J.A. Macoska, H.H. He, C. Cai, Reactivation of AR-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37(6), 710–721 (2018). https://doi.org/10.1038/onc.2017.385
J.V. Swinnen, H. Heemers, T.V. de Sande, E.D. Schrijver, K. Brusselmans, W. Heyns, G. Verhoeven, Androgens, lipogenesis and prostate cancer. J. Steroid Biochem. Mol. Biol. 92(4), 273–279 (2004). https://doi.org/10.1016/j.jsbmb.2004.10.013
W.-C. Huang, X. Li, J. Liu, J. Lin, L.W.K. Chung, Activation of AR, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res. 10(1), 133–142 (2012). https://doi.org/10.1158/1541-7786.MCR-11-0206
M. Chen, J. Zhang, K. Sampieri, J.G. Clohessy, L. Mendez, E. Gonzalez-Billalabeitia, X.S. Liu, Y.R. Lee, J. Fung, J.M. Katon, A.V. Menon, K.A. Webster, C. Ng, M.D. Palumbieri, M.S. Diolombi, S.B. Breitkopf, J. Teruya-Feldstein, S. Signoretti, R.T. Bronson, J.M. Asara, M. Castillo-Martin, C. Cordon-Cardo, P.P. Pandolfi, An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat. Genet. 50(2), 206–218 (2018). https://doi.org/10.1038/s41588-017-0027-2
C. Yokoyama, X. Wang, M.R. Briggs, A. Admon, J. Wu, X. Hua, J.L. Goldstein, M.S. Brown, SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75(1), 187–197 (1993). https://doi.org/10.1016/S0092-8674(05)80095-9
W. Shao, P.J. Espenshade, Expanding roles for SREBP in metabolism. Cell Metab. 16(4), 414–419 (2012). https://doi.org/10.1016/j.cmet.2012.09.002
S.L. Ettinger, R. Sobel, T.G. Whitmore, M. Akbari, D.R. Bradley, M.E. Gleave, C.C. Nelson, Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 64(6), 2212–2221 (2004)
H. Heemers, G. Verrijdt, S. Organe, F. Claessens, W. Heyns, G. Verhoeven, J.V. Swinnen, Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the AR. J. Biol. Chem. 279(29), 30880–30887 (2004). https://doi.org/10.1074/jbc.M401615200
J.V. Swinnen, W. Ulrix, W. Heyns, G. Verhoeven, Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl. Acad. Sci. 94(24), 12975–12980 (1997). https://doi.org/10.1073/pnas.94.24.12975
W.-C. Huang, H.E. Zhau, L.W.K. Chung, AR survival signaling is blocked by anti-β2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J. Biol. Chem. 285(11), 7947–7956 (2010). https://doi.org/10.1074/jbc.M109.092759
E. Rysman, K. Brusselmans, K. Scheys, L. Timmermans, R. Derua, S. Munck, P.P. Van Veldhoven, D. Waltregny, V.W. Daniëls, J. Machiels, F. Vanderhoydonc, K. Smans, E. Waelkens, G. Verhoeven, J.V. Swinnen, De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70(20), 8117 (2010). https://doi.org/10.1158/0008-5472.CAN-09-3871
K. Simons, D. Toomre, Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31 (2000). https://doi.org/10.1038/35036052
L. Li, C.H. Ren, S.A. Tahir, C. Ren, T.C. Thompson, Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. 23(24), 9389–9404 (2003). https://doi.org/10.1128/MCB.23.24.9389-9404.2003
R.M. Young, D. Holowka, B. Baird, A lipid raft environment enhances lyn kinase activity by protecting the active site tyrosine from dephosphorylation. J. Biol. Chem. 278(23), 20746–20752 (2003). https://doi.org/10.1074/jbc.M211402200
K.R. Rice, M.O. Koch, L. Cheng, T.A. Masterson, Dyslipidemia, statins and prostate cancer. Expert Rev. Anticancer Ther. 12(7), 981–990 (2012). https://doi.org/10.1586/era.12.75
B. Cinar, N.K. Mukhopadhyay, G. Meng, M.R. Freeman, Phosphoinositide 3-kinase-independent non-genomic signals transit from the AR to Akt1 in membrane raft microdomains. J. Biol. Chem. 282(40), 29584–29593 (2007). https://doi.org/10.1074/jbc.M703310200
R.V. Farese, T.C. Walther, Lipid droplets finally get a little R-E-S-P-E-C-T. Cell 139(5), 855–860 (2009). https://doi.org/10.1016/j.cell.2009.11.005
T. Petan, E. Jarc, M. Jusović, Lipid droplets in cancer: guardians of fat in a stressful world. Molecules 23(8), E1941 (2018). https://doi.org/10.3390/molecules23081941
K. Bensaad, E. Favaro, A. Lewis Caroline, B. Peck, S. Lord, M. Collins Jennifer, E. Pinnick Katherine, S. Wigfield, M. Buffa Francesca, J.-L. Li, Q. Zhang, J.O. Wakelam Michael, F. Karpe, A. Schulze, L. Harris Adrian, Fatty Acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9(1), 349–365 (2014). https://doi.org/10.1016/j.celrep.2014.08.056
A.G. Cabodevilla, L. Sánchez-Caballero, E. Nintou, V.G. Boiadjieva, F. Picatoste, A. Gubern, E. Claro, Cell survival during complete nutrient deprivation depends on lipid droplet-fueled β-oxidation of fatty acids. J. Biol. Chem. 288(39), 27777–27788 (2013). https://doi.org/10.1074/jbc.M113.466656
S. Koizume, Y. Miyagi, Lipid droplets: a key cellular organelle associated with cancer cell survival under normoxia and hypoxia. Int. J. Mol. Sci. 17(9), 1430 (2016). https://doi.org/10.3390/ijms17091430
J.V. Swinnen, G. Verhoeven, Androgens and the control of lipid metabolism in human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 65(1), 191–198 (1998). https://doi.org/10.1016/S0960-0760(97)00187-8
S. Yue, J. Li, S.Y. Lee, H.J. Lee, T. Shao, B. Song, L. Cheng, T.A. Masterson, X. Liu, T.L. Ratliff, J.X. Cheng, Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19(3), 393–406 (2014). https://doi.org/10.1016/j.cmet.2014.01.019
J.V. Swinnen, T. Roskams, S. Joniau, H. Van Poppel, R. Oyen, L. Baert, W. Heyns, G. Verhoeven, Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer 98(1), 19–22 (2002). https://doi.org/10.1002/ijc.10127
T. Van de Sande, T. Roskams, E. Lerut, S. Joniau, H. Van Poppel, G. Verhoeven, J.V. Swinnen, High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol. 206(2), 214–219 (2005). https://doi.org/10.1002/path.1760
T. Migita, S. Ruiz, A. Fornari, M. Fiorentino, C. Priolo, G. Zadra, F. Inazuka, C. Grisanzio, E. Palescandolo, E. Shin, C. Fiore, W. Xie, A.L. Kung, P.G. Febbo, A. Subramanian, L. Mucci, J. Ma, S. Signoretti, M. Stampfer, W.C. Hahn, S. Finn, M. Loda, Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 101(7), 519–532 (2009). https://doi.org/10.1093/jnci/djp030
S. Hamada, A. Horiguchi, K. Kuroda, K. Ito, T. Asano, K. Miyai, K. Iwaya, Increased fatty acid synthase expression in prostate biopsy cores predicts higher Gleason score in radical prostatectomy specimen. BMC Clin. Pathol. 14(1), 3 (2014). https://doi.org/10.1186/1472-6890-14-3
G. Zadra, C.F. Ribeiro, P. Chetta, Y. Ho, S. Cacciatore, X. Gao, S. Syamala, C. Bango, C. Photopoulos, Y. Huang, S. Tyekucheva, D.C. Bastos, J. Tchaicha, B. Lawney, T. Uo, L. D’Anello, A. Csibi, R. Kalekar, B. Larimer, L. Ellis, L.M. Butler, C. Morrissey, K. McGovern, V.J. Palombella, J.L. Kutok, U. Mahmood, S. Bosari, J. Adams, S. Peluso, S.M. Dehm, S.R. Plymate, M. Loda, Inhibition of de novo lipogenesis targets AR signaling in castration-resistant prostate cancer. Proc. Natl. Acad. Sci. 116(2), 631–640 (2019). https://doi.org/10.1073/pnas.1808834116
E. Furuta, S.K. Pai, R. Zhan, S. Bandyopadhyay, M. Watabe, Y.-Y. Mo, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, S. Kamada, K. Saito, M. Iiizumi, W. Liu, J. Ericsson, K. Watabe, Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res. 68(4), 1003 (2008). https://doi.org/10.1158/0008-5472.CAN-07-2489
X. Gang, Y. Yang, J. Zhong, K. Jiang, Y. Pan, R.J. Karnes, J. Zhang, W. Xu, G. Wang, H. Huang, P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget 7(12), 15135–15149 (2016). https://doi.org/10.18632/oncotarget.7715
S. Kim, X. Yang, Q. Li, M. Wu, L. Costyn, Z. Beharry, M.G. Bartlett, H. Cai, Myristoylation of Src kinase mediates Src-induced and high-fat diet–accelerated prostate tumor progression in mice. J. Biol. Chem. 292(45), 18422–18433 (2017). https://doi.org/10.1074/jbc.M117.798827
H. Cai, D.A. Smith, S. Memarzadeh, C.A. Lowell, J.A. Cooper, O.N. Witte, Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc. Natl. Acad. Sci. 108(16), 6579–6584 (2011). https://doi.org/10.1073/pnas.1103904108
F.L. Zhang, P.J. Casey, Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65(1), 241–269 (1996). https://doi.org/10.1146/annurev.bi.65.070196.001325
B.M. Wasko, A. Dudakovic, R.J. Hohl, Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharmacol. Exp. Ther. 337(2), 540 (2011). https://doi.org/10.1124/jpet.110.175521
J.E. Reilly, J.D. Neighbors, R.J. Hohl, Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biol. Ther. 18(11), 872–882 (2016). https://doi.org/10.1080/15384047.2016.1219817
N.M. Zacharias, C. McCullough, S. Shanmugavelandy, J. Lee, Y. Lee, P. Dutta, J. McHenry, L. Nguyen, W. Norton, L.W. Jones, P.K. Bhattacharya, Metabolic differences in glutamine utilization lead to metabolic vulnerabilities in prostate cancer. Sci. Rep. 7(1), 16159 (2017). https://doi.org/10.1038/s41598-017-16327-z
S.M. Fendt, E.L. Bell, M.A. Keibler, B.A. Olenchock, J.R. Mayers, T.M. Wasylenko, N.I. Vokes, L. Guarente, M.G. Vander Heiden, G. Stephanopoulos, Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat. Commun. 4, 2236 (2013). https://doi.org/10.1038/ncomms3236
A.R. Mullen, W.W. Wheaton, E.S. Jin, P.H. Chen, L.B. Sullivan, T. Cheng, Y. Yang, W.M. Linehan, N.S. Chandel, R.J. DeBerardinis, Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381), 385–388 (2011). https://doi.org/10.1038/nature10642
C.M. Metallo, P.A. Gameiro, E.L. Bell, K.R. Mattaini, J. Yang, K. Hiller, C.M. Jewell, Z.R. Johnson, D.J. Irvine, L. Guarente, J.K. Kelleher, M.G. Vander Heiden, O. Iliopoulos, G. Stephanopoulos, Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481(7381), 380–384 (2011). https://doi.org/10.1038/nature10602
N. Zaidi, J.V. Swinnen, K. Smans, ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 72(15), 3709–3714 (2012). https://doi.org/10.1158/0008-5472.CAN-11-4112
S. Shah, W.J. Carriveau, J. Li, S.L. Campbell, P.K. Kopinski, H.W. Lim, N. Daurio, S. Trefely, K.J. Won, D.C. Wallace, C. Koumenis, A. Mancuso, K.E. Wellen, Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget 7(28), 43713–43730 (2016). https://doi.org/10.18632/oncotarget.9666
A. Beckers, S. Organe, L. Timmermans, K. Scheys, A. Peeters, K. Brusselmans, G. Verhoeven, J.V. Swinnen, Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67(17), 8180–8187 (2007). https://doi.org/10.1158/0008-5472.CAN-07-0389
J.V. Swinnen, P.P. Van Veldhoven, L. Timmermans, E. De Schrijver, K. Brusselmans, F. Vanderhoydonc, T. Van de Sande, H. Heemers, W. Heyns, G. Verhoeven, Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun. 302(4), 898–903 (2003). https://doi.org/10.1016/S0006-291X(03)00265-1
B. Peck, Z.T. Schug, Q. Zhang, B. Dankworth, D.T. Jones, E. Smethurst, R. Patel, S. Mason, M. Jiang, R. Saunders, M. Howell, R. Mitter, B. Spencer-Dene, G. Stamp, L. McGarry, D. James, E. Shanks, E.O. Aboagye, S.E. Critchlow, H.Y. Leung, A.L. Harris, M.J.O. Wakelam, E. Gottlieb, A. Schulze, Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab. 4(1), 6 (2016). https://doi.org/10.1186/s40170-016-0146-8
R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, P.S. Nelson, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447–4454 (2008). https://doi.org/10.1158/0008-5472.CAN-08-0249
D.J. Mener, Prostate specific antigen reduction following statin therapy: mechanism of action and review of the literature. IUBMB Life 62(8), 584–590 (2010). https://doi.org/10.1002/iub.355
A.D. Raval, D. Thakker, H. Negi, A. Vyas, M.W. Salkini, Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 19, 151 (2016). https://doi.org/10.1038/pcan.2015.58
C.R. Sirtori, The pharmacology of statins. Pharmacol. Res. 88, 3–11 (2014). https://doi.org/10.1016/j.phrs.2014.03.002
Y. Chen, M. Hughes-Fulford, Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 91(1), 41–45 (2001). https://doi.org/10.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2
Y. Zhang, K.L. Ma, X.Z. Ruan, B.C. Liu, Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. Int. J. Biol. Sci. 12(5), 569–579 (2016). https://doi.org/10.7150/ijbs.14027
J.R. Krycer, A.J. Brown, Cross-talk between the AR and the liver X receptor. J. Biol. Chem. 286(23), 20637–20647 (2011). https://doi.org/10.1074/jbc.M111.227082
N. Zelcer, C. Hong, R. Boyadjian, P. Tontonoz, LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL Receptor. Science 325(5936), 100 (2009). https://doi.org/10.1126/science.1168974
J.J. Repa, S.D. Turley, J.M.A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R.A. Heyman, J.M. Dietschy, D.J. Mangelsdorf, Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289(5484), 1524 (2000). https://doi.org/10.1126/science.289.5484.1524
D.J. Peet, S.D. Turley, W. Ma, B.A. Janowski, J.-M.A. Lobaccaro, R.E. Hammer, D.J. Mangelsdorf, Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93(5), 693–704 (1998). https://doi.org/10.1016/S0092-8674(00)81432-4
A.J.C. Pommier, G. Alves, E. Viennois, S. Bernard, Y. Communal, B. Sion, G. Marceau, C. Damon, K. Mouzat, F. Caira, S. Baron, J.M.A. Lobaccaro, Liver X receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 29, 2712 (2010). https://doi.org/10.1038/onc.2010.30
C.-Y. Lin, J.-Å. Gustafsson, Targeting liver X receptors in cancer therapeutics. Nat. Rev. Cancer 15, 216 (2015). https://doi.org/10.1038/nrc3912
M.A. Alfaqih, E.R. Nelson, W. Liu, R. Safi, J.S. Jasper, E. Macias, J. Geradts, J.W. Thompson, L.G. Dubois, M.R. Freeman, C.Y. Chang, J.T. Chi, D.P. McDonnell, S.J. Freedland, CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer. Cancer Res. 77(7), 1662–1673 (2017). https://doi.org/10.1158/0008-5472.CAN-16-2738
Y. Liu, Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9(3), 230–234 (2006)
T.W. Flaig, M. Salzmann-Sullivan, L.J. Su, Z. Zhang, M. Joshi, M.A. Gijon, J. Kim, J.J. Arcaroli, A. Van Bokhoven, M.S. Lucia, F.G. La Rosa, I.R. Schlaepfer, Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget 8(34), 56051–56065 (2017). https://doi.org/10.18632/oncotarget.17359
I.R. Schlaepfer, L. Rider, L.U. Rodrigues, M.A. Gijon, C.T. Pac, L. Romero, A. Cimic, S.J. Sirintrapun, L.M. Glode, R.H. Eckel, S.D. Cramer, Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol. Cancer Ther. 13(10), 2361–2371 (2014). https://doi.org/10.1158/1535-7163.MCT-14-0183
J.B. Tennakoon, Y. Shi, J.J. Han, E. Tsouko, M.A. White, A.R. Burns, A. Zhang, X. Xia, O.R. Ilkayeva, L. Xin, M.M. Ittmann, F.G. Rick, A.V. Schally, D.E. Frigo, Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 33, 5251–5261 (2014). https://doi.org/10.1038/onc.2013.463
G. Yu, C.J. Cheng, S.C. Lin, Y.C. Lee, D.E. Frigo, L.Y. Yu-Lee, G.E. Gallick, M.A. Titus, L.K. Nutt, S.H. Lin, Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II. Cancer Res. 78(10), 2490–2502 (2018). https://doi.org/10.1158/0008-5472.CAN-17-2392
R.J.A. Wanders, Metabolic functions of peroxisomes in health and disease. Biochimie 98, 36–44 (2014). https://doi.org/10.1016/j.biochi.2013.08.022
J. Luo, S. Zha, W.R. Gage, T.A. Dunn, J.L. Hicks, C.J. Bennett, C.M. Ewing, E.A. Platz, S. Ferdinandusse, R.J. Wanders, J.M. Trent, W.B. Isaacs, A.M. De Marzo, α-Methylacyl-CoA racemase a new molecular marker for prostate cancer. Cancer Res. 62(8), 2220–2226 (2002)
M.D. Lloyd, M. Yevglevskis, G.L. Lee, P.J. Wood, M.D. Threadgill, T.J. Woodman, α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog. Lipid Res. 52(2), 220–230 (2013). https://doi.org/10.1016/j.plipres.2013.01.001
S. Zha, S. Ferdinandusse, J.L. Hicks, S. Denis, T.A. Dunn, R.J. Wanders, J. Luo, A.M. De Marzo, W.B. Isaacs, Peroxisomal branched chain fatty acid β-oxidation pathway is upregulated in prostate cancer. Prostate 63(4), 316–323 (2005). https://doi.org/10.1002/pros.20177
D.R. Wise, C.B. Thompson, Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35(8), 427–433 (2010). https://doi.org/10.1016/j.tibs.2010.05.003
D. Daye, K.E. Wellen, Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23(4), 362–369 (2012). https://doi.org/10.1016/j.semcdb.2012.02.002
D.R. Wise, R.J. DeBerardinis, A. Mancuso, N. Sayed, X.Y. Zhang, H.K. Pfeiffer, I. Nissim, E. Daikhin, M. Yudkoff, S.B. McMahon, C.B. Thompson, Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. 105(48), 18782–18787 (2008). https://doi.org/10.1073/pnas.0810199105
B.J. Altman, Z.E. Stine, C.V. Dang, From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16(10), 619–634 (2016). https://doi.org/10.1038/nrc.2016.71
M.A. White, C. Lin, K. Rajapakshe, J. Dong, Y. Shi, E. Tsouko, R. Mukhopadhyay, D. Jasso, W. Dawood, C. Coarfa, D.E. Frigo, Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer. Mol. Cancer Res. 15(8), 1017–1028 (2017). https://doi.org/10.1158/1541-7786.MCR-16-0480
Q. Wang, J. Tiffen, C.G. Bailey, M.L. Lehman, W. Ritchie, L. Fazli, C. Metierre, Y.J. Feng, E. Li, M. Gleave, G. Buchanan, C.C. Nelson, J.E. Rasko, J. Holst, Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J. Natl. Cancer Inst. 105(19), 1463–1473 (2013). https://doi.org/10.1093/jnci/djt241
P. Gao, I. Tchernyshyov, T.C. Chang, Y.S. Lee, K. Kita, T. Ochi, K.I. Zeller, A.M. De Marzo, J.E. Van Eyk, J.T. Mendell, C.V. Dang, c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239), 762–765 (2009). https://doi.org/10.1038/nature07823
K. Ellwood-Yen, T.G. Graeber, J. Wongvipat, M.L. Iruela-Arispe, J. Zhang, R. Matusik, G.V. Thomas, C.L. Sawyers, Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4(3), 223–238 (2003). https://doi.org/10.1016/s1535-6108(03)00197-1
J.J. Harding, M.L. Telli, P.N. Munster, M.H. Le, C. Molineaux, M.K. Bennett, E. Mittra, H.A. Burris, A.S. Clark, M. Dunphy, F. Meric-Bernstam, M.R. Patel, A. DeMichele, J.R. Infante, Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J. Clin. Oncol. 33(15 Suppl), 2512–2512 (2015). https://doi.org/10.1200/jco.2015.33.15_suppl.2512
J.M. Rhoads, R.A. Argenzio, W. Chen, L.M. Graves, L.L. Licato, A.T. Blikslager, J. Smith, J. Gatzy, D.A. Brenner, Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, RAF-independent mechanism. Gastroenterology 118(1), 90–100 (2000). https://doi.org/10.1016/S0016-5085(00)70417-3
P. Dalle Pezze, S. Ruf, A.G. Sonntag, M. Langelaar-Makkinje, P. Hall, A.M. Heberle, P. Razquin Navas, K. van Eunen, R.C. Tölle, J.J. Schwarz, H. Wiese, B. Warscheid, J. Deitersen, B. Stork, E. Fäßler, S. Schäuble, U. Hahn, P. Horvatovich, D.P. Shanley, K. Thedieck, A systems study reveals concurrent activation of AMPK and mTOR by amino acids. Nat. Commun. 7, 13254 (2016). https://doi.org/10.1038/ncomms13254
S.A. Hawley, J. Boudeau, J.L. Reid, K.J. Mustard, L. Udd, T.P. Mäkelä, D.R. Alessi, D.G. Hardie, Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2(4), 28 (2003). https://doi.org/10.1186/1475-4924-2-28
A. Woods, S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, D. Carling, LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13(22), 2004–2008 (2003). https://doi.org/10.1016/j.cub.2003.10.031
R.J. Shaw, M. Kosmatka, N. Bardeesy, R.L. Hurley, L.A. Witters, R.A. DePinho, L.C. Cantley, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. 101(10), 3329–3335 (2004). https://doi.org/10.1073/pnas.0308061100
D.E. Frigo, M.K. Howe, B.M. Wittmann, A.M. Brunner, I. Cushman, Q. Wang, M. Brown, A.R. Means, D.P. McDonnell, CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 71(2), 528–537 (2011). https://doi.org/10.1158/0008-5472.CAN-10-2581
L.G. Karacosta, B.A. Foster, G. Azabdaftari, D.M. Feliciano, A.M. Edelman, A Regulatory feedback loop between Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the AR in prostate cancer progression. J. Biol. Chem. 287(29), 24832–24843 (2012). https://doi.org/10.1074/jbc.M112.370783
C.E. Massie, A. Lynch, A. Ramos-Montoya, J. Boren, R. Stark, L. Fazli, A. Warren, H. Scott, B. Madhu, N. Sharma, H. Bon, V. Zecchini, D.M. Smith, G.M. Denicola, N. Mathews, M. Osborne, J. Hadfield, S. Macarthur, B. Adryan, S.K. Lyons, K.M. Brindle, J. Griffiths, M.E. Gleave, P.S. Rennie, D.E. Neal, I.G. Mills, The AR fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30(13), 2719–2733 (2011). https://doi.org/10.1038/emboj.2011.158
M.L. Schulte, A. Fu, P. Zhao, J. Li, L. Geng, S.T. Smith, J. Kondo, R.J. Coffey, M.O. Johnson, J.C. Rathmell, J.T. Sharick, M.C. Skala, J.A. Smith, J. Berlin, M.K. Washington, M.L. Nickels, H.C. Manning, Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat. Med. 24(2), 194–202 (2018). https://doi.org/10.1038/nm.4464
Y. Liu, T. Zhao, Z. Li, L. Wang, S. Yuan, L. Sun, The role of ASCT2 in cancer: a review. Eur. J. Pharmacol. 837, 81–87 (2018). https://doi.org/10.1016/j.ejphar.2018.07.007
L. Feun, M. You, C.J. Wu, M.T. Kuo, M. Wangpaichitr, S. Spector, N. Savaraj, Arginine deprivation as a targeted therapy for cancer. Curr. Pharm. Des. 14(11), 1049–1057 (2008). https://doi.org/10.2174/138161208784246199
R.H. Kim, J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, J.U. Jung, R. Gandour-Edwards, F.Y.S. Chuang, R.J. Bold, H.-J. Kung, Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 69(2), 700 (2009). https://doi.org/10.1158/0008-5472.can-08-3157
R. Keshet, P. Szlosarek, A. Carracedo, A. Erez, Rewiring urea cycle metabolism in cancer to support anabolism. Nat. Rev. Cancer 18(10), 634–645 (2018). https://doi.org/10.1038/s41568-018-0054-z
J.S. Lee, L. Adler, H. Karathia, N. Carmel, S. Rabinovich, N. Auslander, R. Keshet, N. Stettner, A. Silberman, L. Agemy, D. Helbling, R. Eilam, Q. Sun, A. Brandis, S. Malitsky, M. Itkin, H. Weiss, S. Pinto, S. Kalaora, R. Levy, E. Barnea, A. Admon, D. Dimmock, N. Stern-Ginossar, A. Scherz, S.C.S. Nagamani, M. Unda, D.M. Wilson 3rd, R. Elhasid, A. Carracedo, Y. Samuels, S. Hannenhalli, E. Ruppin, A. Erez, Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures. Cell 174(6), 1559–1570.e1522 (2018). https://doi.org/10.1016/j.cell.2018.07.019
A. Husson, C. Brasse-Lagnel, A. Fairand, S. Renouf, A. Lavoinne, Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycle. Eur. J. Biochem. 270(9), 1887–1899 (2003). https://doi.org/10.1046/j.1432-1033.2003.03559.x
C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski, M.A. Clark, Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62(19), 5443–5450 (2002)
E.C. Hsueh, S.M. Knebel, W.-H. Lo, Y.-C. Leung, P.N.-M. Cheng, C.-T. Hsueh, Deprivation of arginine by recombinant human arginase in prostate cancer cells. J. Hematol. Oncol. 5, 17 (2012). https://doi.org/10.1186/1756-8722-5-17
S.L. Nowotarski, P.M. Woster, R.A. Casero, Polyamines and cancer: implications for chemoprevention and chemotherapy. Expert Rev. Mol. Med. 15, e3 (2013). https://doi.org/10.1017/erm.2013.3
G.E. Bai, S. Kasper, R.J. Matusik, P.S. Rennie, J.A. Moshier, A. Krongrad, Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J. Androl. 19(2), 127–135 (1998). https://doi.org/10.1002/j.1939-4640.1998.tb01981.x
A. Shukla-Dave, M. Castillo-Martin, M. Chen, J. Lobo, N. Gladoun, A. Collazo-Lorduy, F.M. Khan, V. Ponomarev, Z. Yi, W. Zhang, P.P. Pandolfi, H. Hricak, C. Cordon-Cardo, Ornithine decarboxylase is sufficient for prostate tumorigenesis via AR signaling. Am. J. Pathol. 186, 3131 (2016). https://doi.org/10.1016/j.ajpath.2016.08.021
B.H. Devens, R.S. Weeks, M.R. Burns, C.L. Carlson, M.K. Brawer, Polyamine depletion therapy in prostate cancer. Prostate Cancer Prostatic Dis. 3, 275 (2000). https://doi.org/10.1038/sj.pcan.4500420
G.F. Giskeødegård, H. Bertilsson, K.M. Selnæs, A.J. Wright, T.F. Bathen, T. Viset, J. Halgunset, A. Angelsen, I.S. Gribbestad, M.-B. Tessem, Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 8(4), e62375 (2013). https://doi.org/10.1371/journal.pone.0062375
M.G. Swanson, A.S. Zektzer, Z.L. Tabatabai, J. Simko, S. Jarso, K.R. Keshari, L. Schmitt, P.R. Carroll, K. Shinohara, D.B. Vigneron, J. Kurhanewicz, Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn. Reson. Med. 55(6), 1257–1264 (2006). https://doi.org/10.1002/mrm.20909
L.L. Cheng, C.-l. Wu, M.R. Smith, R.G. Gonzalez, Non‐destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett. 494(1-2), 112–116 (2001). https://doi.org/10.1016/S0014-5793(01)02329-8
M.J. Corbin, J.M. Ruiz-Echevarría, One-carbon metabolism in prostate cancer: the role of androgen signaling. Int. J. Mol. Sci. 17(8), E1208 (2016). https://doi.org/10.3390/ijms17081208
O. Shuvalov, A. Petukhov, A. Daks, O. Fedorova, E. Vasileva, N.A. Barlev, One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy. Oncotarget 8(14), 23955–23977 (2017). https://doi.org/10.18632/oncotarget.15053
A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, J. Yu, B. Laxman, R. Mehra, R.J. Lonigro, Y. Li, M.K. Nyati, A. Ahsan, S. Kalyana-Sundaram, B. Han, X. Cao, J. Byun, G.S. Omenn, D. Ghosh, S. Pennathur, D.C. Alexander, A. Berger, J.R. Shuster, J.T. Wei, S. Varambally, C. Beecher, A.M. Chinnaiyan, Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910 (2009). https://doi.org/10.1038/nature07762
A.A. Shafi, V. Putluri, J.M. Arnold, E. Tsouko, S. Maity, J.M. Roberts, C. Coarfa, D.E. Frigo, N. Putluri, A. Sreekumar, N.L. Weigel, Differential regulation of metabolic pathways by AR and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6(31), 31997–32012 (2015). https://doi.org/10.18632/oncotarget.5585
S. Ottaviani, G.N. Brooke, C. O’Hanlon-Brown, J. Waxman, S. Ali, L. Buluwela, Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells. J. Mol. Endocrinol. 51(3), 301–312 (2013). https://doi.org/10.1530/jme-13-0169
W.G. Nelson, A.M. De Marzo, S. Yegnasubramanian, Epigenetic alterations in human prostate cancers. Endocrinology 150(9), 3991–4002 (2009). https://doi.org/10.1210/en.2009-0573
S. Yegnasubramanian, J. Kowalski, M.L. Gonzalgo, M. Zahurak, S. Piantadosi, P.C. Walsh, G.S. Bova, A.M. De Marzo, W.B. Isaacs, W.G. Nelson, Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64(6), 1975 (2004). https://doi.org/10.1158/0008-5472.can-03-3972
C. Jerónimo, R. Henrique, M.O. Hoque, E. Mambo, F.R. Ribeiro, G. Varzim, J. Oliveira, M.R. Teixeira, C. Lopes, D. Sidransky, A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 10(24), 8472 (2004). https://doi.org/10.1158/1078-0432.ccr-04-0894
R. Maruyama, S. Toyooka, K.O. Toyooka, A.K. Virmani, S. Zöchbauer-Müller, A.J. Farinas, J.D. Minna, J. McConnell, E.P. Frenkel, A.F. Gazdar, Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8(2), 514 (2002)
A.R. Florl, C. Steinhoff, M. Müller, H.H. Seifert, C. Hader, R. Engers, R. Ackermann, W.A. Schulz, Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91(5), 985–994 (2004). https://doi.org/10.1038/sj.bjc.6602030
A. Padar, U.G. Sathyanarayana, M. Suzuki, R. Maruyama, J.T. Hsieh, E.P. Frenkel, J.D. Minna, A.F. Gazdar, Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9(13), 4730–4734 (2003)
M. Yamanaka, M. Watanabe, Y. Yamada, A. Takagi, T. Murata, H. Takahashi, H. Suzuki, H. Ito, H. Tsukino, T. Katoh, Y. Sugimura, T. Shiraishi, Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer 106(3), 382–387 (2003). https://doi.org/10.1002/ijc.11227
J. Ellinger, P.J. Bastian, T. Jurgan, K. Biermann, P. Kahl, L.C. Heukamp, N. Wernert, S.C. Müller, A. von Ruecker, CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71(1), 161–167 (2008). https://doi.org/10.1016/j.urology.2007.09.056
D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, H. Hermeking, Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65(10), 4218 (2005). https://doi.org/10.1158/0008-5472.can-04-4407
S.P. Antoinette, F. Ruth, W. Karen, L. Mark, The emerging roles of DNA methylation in the clinical management of prostate cancer. Endoc. Relat. Cancer 13(2), 357–377 (2006). https://doi.org/10.1677/erc.1.01184
E. Lee, J. Wang, K. Yumoto, Y. Jung, F.C. Cackowski, A.M. Decker, Y. Li, R.T. Franceschi, K.J. Pienta, R.S. Taichman, DNMT1 Regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia 18(9), 553–566 (2016). https://doi.org/10.1016/j.neo.2016.07.007
S.R. Morey Kinney, M.T. Moser, M. Pascual, J.M. Greally, B.A. Foster, A.R. Karpf, Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol. Cell. Biol. 30(17), 4159 (2010). https://doi.org/10.1128/mcb.00235-10
M.T. McCabe, J.A. Low, S. Daignault, M.J. Imperiale, K.J. Wojno, M.L. Day, Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res. 66(1), 385 (2006). https://doi.org/10.1158/0008-5472.can-05-2020
R. Singal, K. Ramachandran, E. Gordian, C. Quintero, W. Zhao, I.M. Reis, Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin. Genitourin. Cancer 13(1), 22–31 (2015). https://doi.org/10.1016/j.clgc.2014.07.008
R.A. Casero Jr., L.J. Marton, Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 6, 373 (2007). https://doi.org/10.1038/nrd2243
E.W. Gerner, F.L. Meyskens Jr., Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4, 781 (2004). https://doi.org/10.1038/nrc1454
K. Soda, The mechanisms by which polyamines accelerate tumor spread. J. Exp. Clin. Cancer Res. 30(1), 95–95 (2011). https://doi.org/10.1186/1756-9966-30-95
B.G. Cipolla, R. Havouis, J.-P. Moulinoux, Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed. Pharmacother. 64(5), 363–368 (2010). https://doi.org/10.1016/j.biopha.2009.09.022
I.G. Fantus, H.J. Goldberg, C.I. Whiteside, D. Topic, The hexosamine biosynthesis pathway, in The Diabetic Kidney, ed. by P. Cortes, C. E. Mogensen, (Humana Press, Totowa, NJ, 2006), pp. 117–133. https://doi.org/10.1007/978-1-59745-153-6_7
H.M. Itkonen, N. Engedal, E. Babaie, M. Luhr, I.J. Guldvik, S. Minner, J. Hohloch, M.C. Tsourlakis, T. Schlomm, I.G. Mills, UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene 34(28), 3744–3750 (2015). https://doi.org/10.1038/onc.2014.307
H.M. Itkonen, S. Minner, I.J. Guldvik, M.J. Sandmann, M.C. Tsourlakis, V. Berge, A. Svindland, T. Schlomm, I.G. Mills, O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 73(16), 5277–5287 (2013). https://doi.org/10.1158/0008-5472.CAN-13-0549
H.M. Itkonen, I.G. Mills, N-linked glycosylation supports cross-talk between receptor tyrosine kinases and AR. PLoS One 8(5), e65016 (2013). https://doi.org/10.1371/journal.pone.0065016
T. Kamigaito, T. Okaneya, M. Kawakubo, H. Shimojo, O. Nishizawa, J. Nakayama, Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 17(1), 18–22 (2014). https://doi.org/10.1038/pcan.2013.56
T.P. Lynch, C.M. Ferrer, S.R. Jackson, K.S. Shahriari, K. Vosseller, M.J. Reginato, Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem. 287(14), 11070–11081 (2012). https://doi.org/10.1074/jbc.M111.302547
A.K. Kaushik, A. Shojaie, K. Panzitt, R. Sonavane, H. Venghatakrishnan, M. Manikkam, A. Zaslavsky, V. Putluri, V.T. Vasu, Y.Q. Zhang, A.S. Khan, S. Lloyd, A.T. Szafran, S. Dasgupta, D.A. Bader, F. Stossi, H.W. Li, S. Samanta, X.H. Cao, E. Tsouko, S.X. Huang, D.E. Frigo, L. Chan, D.P. Edwards, B.A. Kaipparettu, N. Mitsiades, N.L. Weigel, M. Mancini, S.E. McGuire, R. Mehra, M.M. Ittmann, A.M. Chinnaiyan, N. Putluri, G.S. Palapattu, G. Michailidis, A. Sreekumar, Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat. Commun. 7, 11612 (2016). https://doi.org/10.1038/ncomms11612
L. Galluzzi, F. Pietrocola, J.M. Bravo-San Pedro, R.K. Amaravadi, E.H. Baehrecke, F. Cecconi, P. Codogno, J. Debnath, D.A. Gewirtz, V. Karantza, A. Kimmelman, S. Kumar, B. Levine, M.C. Maiuri, S.J. Martin, J. Penninger, M. Piacentini, D.C. Rubinsztein, H.U. Simon, A. Simonsen, A.M. Thorburn, G. Velasco, K.M. Ryan, G. Kroemer, Autophagy in malignant transformation and cancer progression. EMBO J. 34(7), 856–880 (2015). https://doi.org/10.15252/embj.201490784
J. Goldsmith, B. Levine, J. Debnath, Autophagy and cancer metabolism. Methods Enzymol. 542, 25–57 (2014). https://doi.org/10.1016/B978-0-12-416618-9.00002-9
E. Ziparo, S. Petrungaro, E.S. Marini, D. Starace, S. Conti, A. Facchiano, A. Filippini, C. Giampietri, Autophagy in prostate cancer and androgen suppression therapy. Int. J. Mol. Sci. 14(6), 12090–12106 (2013). https://doi.org/10.3390/ijms140612090
X. Xie, J.Y. Koh, S. Price, E. White, J.M. Mehnert, Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 5(4), 410–423 (2015). https://doi.org/10.1158/2159-8290.CD-14-1473
M. Garcia-Fernandez, P. Karras, A. Checinska, E. Canon, G.T. Calvo, G. Gomez-Lopez, M. Cifdaloz, A. Colmenar, L. Espinosa-Hevia, D. Olmeda, M.S. Soengas, Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5. Autophagy 12(10), 1776–1790 (2016). https://doi.org/10.1080/15548627.2016.1199301
U. Santanam, W. Banach-Petrosky, C. Abate-Shen, M.M. Shen, E. White, R.S. DiPaola, Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev. 30(4), 399–407 (2016). https://doi.org/10.1101/gad.274134.115
J.M. Farrow, J.C. Yang, C.P. Evans, Autophagy as a modulator and target in prostate cancer. Nat. Rev. Urol. 11(9), 508–516 (2014). https://doi.org/10.1038/nrurol.2014.196
X. Chen, J. Lu, L. Xia, G. Li, Drug resistance of enzalutamide in CRPC. Curr. Drug Targets 19(6), 613–620 (2018). https://doi.org/10.2174/1389450118666170417144250
H.G. Nguyen, J.C. Yang, H.J. Kung, X.B. Shi, D. Tilki, P.N. Lara Jr., R.W. DeVere White, A.C. Gao, C.P. Evans, Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 33(36), 4521–4530 (2014). https://doi.org/10.1038/onc.2014.25
M. Parikh, J.C. Hyunh, P. Lara, C.X. Pan, D. Robles, C.P. Evans, Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): current results from a phase I study. J. Clin. Oncol. 36(6), 281 (2018). https://doi.org/10.1200/JCO.2018.36.6_suppl.281
B. Kranzbuhler, S. Salemi, A. Mortezavi, T. Sulser, D. Eberli, Combined N-terminal AR and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Prostate 79(2), 206–214 (2019). https://doi.org/10.1002/pros.23725
F. Hu, Y. Zhao, Y. Yu, J.M. Fang, R. Cui, Z.Q. Liu, X.L. Guo, Q. Xu, Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3. Cancer Lett. 416, 24–30 (2018). https://doi.org/10.1016/j.canlet.2017.12.013
R. Cristofani, M. Montagnani Marelli, M.E. Cicardi, F. Fontana, M. Marzagalli, P. Limonta, A. Poletti, R.M. Moretti, Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells. Cell Death Dis. 9(9), 889 (2018). https://doi.org/10.1038/s41419-018-0866-5
Q. Wang, W.Y. He, Y.Z. Zeng, A. Hossain, X. Gou, Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells. Int. Urol. Nephrol. 50(4), 675–686 (2018). https://doi.org/10.1007/s11255-018-1801-5
H. Draz, A.A. Goldberg, V.I. Titorenko, E.S. Tomlinson Guns, S.H. Safe, J.T. Sanderson, Diindolylmethane and its halogenated derivatives induce protective autophagy in human prostate cancer cells via induction of the oncogenic protein AEG-1 and activation of AMP-activated protein kinase (AMPK). Cell. Signal. 40, 172–182 (2017). https://doi.org/10.1016/j.cellsig.2017.09.006
H. Draz, A.A. Goldberg, E.S. Tomlinson Guns, L. Fazli, S. Safe, J.T. Sanderson, Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model. Invest. New Drugs 36(4), 718–725 (2018). https://doi.org/10.1007/s10637-018-0595-8
X. Zhu, M. Zhou, G.Y. Liu, X.L. Huang, W.Y. He, X. Gou, T. Jiang, Autophagy activated by the c-Jun N-terminal kinase-mediated pathway protects human prostate cancer PC3 cells from celecoxib-induced apoptosis. Exp. Ther. Med. 13(5), 2348–2354 (2017). https://doi.org/10.3892/etm.2017.4287
C. Yang, X. Ma, Z. Wang, X. Zeng, Z. Hu, Z. Ye, G. Shen, Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation. Drug Des. Devel. Ther. 11, 431–439 (2017). https://doi.org/10.2147/DDDT.S126964
Y.C. Lin, Y.T. Chang, M. Campbell, T.P. Lin, C.C. Pan, H.C. Lee, J.C. Shih, P.C. Chang, MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci. Rep. 7, 46338 (2017). https://doi.org/10.1038/srep46338
S. Niture, M. Ramalinga, H. Kedir, D. Patacsil, S.S. Niture, J. Li, H. Mani, S. Suy, S. Collins, D. Kumar, TNFAIP8 promotes prostate cancer cell survival by inducing autophagy. Oncotarget 9(42), 26884–26899 (2018). https://doi.org/10.18632/oncotarget.25529
J. Lu, W. Dong, H. He, Z. Han, Y. Zhuo, R. Mo, Y. Liang, J. Zhu, R. Li, H. Qu, L. Zhang, S. Wang, R. Ma, Z. Jia, W. Zhong, Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer. Int. J. Biol. Macromol. 118(Pt A), 599–609 (2018). https://doi.org/10.1016/j.ijbiomac.2018.06.005
C. Commisso, J. Debnath, Macropinocytosis fuels prostate cancer. Cancer Discov. 8(7), 800–802 (2018). https://doi.org/10.1158/2159-8290.CD-18-0513
S.M. Kim, T.T. Nguyen, A. Ravi, P. Kubiniok, B.T. Finicle, V. Jayashankar, L. Malacrida, J. Hou, J. Robertson, D. Gao, J. Chernoff, M.A. Digman, E.O. Potma, B.J. Tromberg, P. Thibault, A.L. Edinger, PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 8(7), 866–883 (2018). https://doi.org/10.1158/2159-8290.CD-17-1215
A.S. Khan, D.E. Frigo, A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. Nat. Rev. Urol. 14(3), 164–180 (2017). https://doi.org/10.1038/nrurol.2016.272
C.V. Vaz, R. Marques, M.G. Alves, P.F. Oliveira, J.E. Cavaco, C.J. Maia, S. Socorro, Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J. Cancer Res. Clin. Oncol. 142(1), 5–16 (2016). https://doi.org/10.1007/s00432-015-1992-4
D. Awad, T.L. Pulliam, C. Lin, S.R. Wilkenfeld, D.E. Frigo, Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. Curr. Opin. Pharmacol. 41, 1–11 (2018). https://doi.org/10.1016/j.coph.2018.03.002
L.M. Butler, M.M. Centenera, J.V. Swinnen, Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocr. Relat. Cancer 23(5), R219–R227 (2016). https://doi.org/10.1530/ERC-15-0556
U.C. Dadwal, E.S. Chang, U. Sankar, AR-CaMKK2 axis in prostate cancer and bone microenvironment. Front. Endocrinol. 9, 335 (2018). https://doi.org/10.3389/fendo.2018.00335
T. Mitani, R. Yamaji, Y. Higashimura, N. Harada, Y. Nakano, H. Inui, Hypoxia enhances transcriptional activity of AR through hypoxia-inducible factor-1alpha in a low androgen environment. J. Steroid Biochem. Mol. Biol. 123(1-2), 58–64 (2011). https://doi.org/10.1016/j.jsbmb.2010.10.009
N.J. Mabjeesh, M.T. Willard, C.E. Frederickson, H. Zhong, J.W. Simons, Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 9(7), 2416–2425 (2003)
R.J. Rebello, R.B. Pearson, R.D. Hannan, L. Furic, Therapeutic approaches targeting MYC-driven prostate cancer. Genes (Basel) 8(2), E71 (2017). https://doi.org/10.3390/genes8020071
C.V. Dang, A. Le, P. Gao, MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15(21), 6479–6483 (2009). https://doi.org/10.1158/1078-0432.CCR-09-0889
C. Priolo, S. Pyne, J. Rose, E.R. Regan, G. Zadra, C. Photopoulos, S. Cacciatore, D. Schultz, N. Scaglia, J. McDunn, A.M. De Marzo, M. Loda, AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 74(24), 7198–7204 (2014). https://doi.org/10.1158/0008-5472.CAN-14-1490
D. Mossmann, S. Park, M.N. Hall, mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer 18(12), 744–757 (2018). https://doi.org/10.1038/s41568-018-0074-8
J.S. Yu, W. Cui, Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development 143(17), 3050–3060 (2016). https://doi.org/10.1242/dev.137075
V. Nogueira, K.C. Patra, N. Hay, Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation. Elife 7, e32213 (2018). https://doi.org/10.7554/eLife.32213
F. Giunchi, M. Fiorentino, M. Loda, The metabolic landscape of prostate cancer. Eur. Urol. Oncol. 2, 28 (2019). https://doi.org/10.1016/j.euo.2018.06.010
J.V. Lee, A. Carrer, S. Shah, N.W. Snyder, S. Wei, S. Venneti, A.J. Worth, Z.F. Yuan, H.W. Lim, S. Liu, E. Jackson, N.M. Aiello, N.B. Haas, T.R. Rebbeck, A. Judkins, K.J. Won, L.A. Chodosh, B.A. Garcia, B.Z. Stanger, M.D. Feldman, I.A. Blair, K.E. Wellen, Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 20(2), 306–319 (2014). https://doi.org/10.1016/j.cmet.2014.06.004
P. Toren, A. Zoubeidi, Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). Int. J. Oncol. 45(5), 1793–1801 (2014). https://doi.org/10.3892/ijo.2014.2601
A. Naguib, G. Mathew, C.R. Reczek, K. Watrud, A. Ambrico, T. Herzka, I.C. Salas, M.F. Lee, N. El-Amine, W. Zheng, M.E. Di Francesco, J.R. Marszalek, D.J. Pappin, N.S. Chandel, L.C. Trotman, Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells. Cell Rep. 23(1), 58–67 (2018). https://doi.org/10.1016/j.celrep.2018.03.032
A. Csibi, S.M. Fendt, C. Li, G. Poulogiannis, A.Y. Choo, D.J. Chapski, S.M. Jeong, J.M. Dempsey, A. Parkhitko, T. Morrison, E.P. Henske, M.C. Haigis, L.C. Cantley, G. Stephanopoulos, J. Yu, J. Blenis, The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153(4), 840–854 (2013). https://doi.org/10.1016/j.cell.2013.04.023
A. Zabala-Letona, A. Arruabarrena-Aristorena, N. Martin-Martin, S. Fernandez-Ruiz, J.D. Sutherland, M. Clasquin, J. Tomas-Cortazar, J. Jimenez, I. Torres, P. Quang, P. Ximenez-Embun, R. Bago, A. Ugalde-Olano, A. Loizaga-Iriarte, I. Lacasa-Viscasillas, M. Unda, V. Torrano, D. Cabrera, S.M. van Liempd, Y. Cendon, E. Castro, S. Murray, A. Revandkar, A. Alimonti, Y. Zhang, A. Barnett, G. Lein, D. Pirman, A.R. Cortazar, L. Arreal, L. Prudkin, I. Astobiza, L. Valcarcel-Jimenez, P. Zuniga-Garcia, I. Fernandez-Dominguez, M. Piva, A. Caro-Maldonado, P. Sanchez-Mosquera, M. Castillo-Martin, V. Serra, N. Beraza, A. Gentilella, G. Thomas, M. Azkargorta, F. Elortza, R. Farras, D. Olmos, A. Efeyan, J. Anguita, J. Munoz, J.M. Falcon-Perez, R. Barrio, T. Macarulla, J.M. Mato, M.L. Martinez-Chantar, C. Cordon-Cardo, A.M. Aransay, K. Marks, J. Baselga, J. Tabernero, P. Nuciforo, B.D. Manning, K. Marjon, A. Carracedo, mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature 547(7661), 109–113 (2017). https://doi.org/10.1038/nature22964
Q. Wang, C.G. Bailey, C. Ng, J. Tiffen, A. Thoeng, V. Minhas, M.L. Lehman, S.C. Hendy, G. Buchanan, C.C. Nelson, J.E. Rasko, J. Holst, AR and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 71(24), 7525–7536 (2011). https://doi.org/10.1158/0008-5472.CAN-11-1821
B.S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty, V.K. Arora, C. Le, J. Koutcher, H. Scher, P.T. Scardino, N. Rosen, C.L. Sawyers, Reciprocal feedback regulation of PI3K and AR signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5), 575–586 (2011). https://doi.org/10.1016/j.ccr.2011.04.008
M.P. Edlind, A.C. Hsieh, PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J. Androl. 16(3), 378–386 (2014). https://doi.org/10.4103/1008-682X.122876
M. Crumbaker, L. Khoja, A.M. Joshua, AR signaling and the PI3K pathway in prostate cancer. Cancers (Basel) 9(4), E34 (2017). https://doi.org/10.3390/cancers9040034
E. Audet-Walsh, C.R. Dufour, T. Yee, F.Z. Zouanat, M. Yan, G. Kalloghlian, M. Vernier, M. Caron, G. Bourque, E. Scarlata, L. Hamel, F. Brimo, A.G. Aprikian, J. Lapointe, S. Chevalier, V. Giguere, Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 31(12), 1228–1242 (2017). https://doi.org/10.1101/gad.299958.117
M. Marhold, E. Tomasich, A. El-Gazzar, G. Heller, A. Spittler, R. Horvat, M. Krainer, P. Horak, HIF1alpha regulates mTOR signaling and viability of prostate cancer stem cells. Mol. Cancer Res. 13(3), 556–564 (2015). https://doi.org/10.1158/1541-7786.MCR-14-0153-T
S.J. Barfeld, H.M. Itkonen, A. Urbanucci, I.G. Mills, Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocr. Relat. Cancer 21(4), T57–T66 (2014). https://doi.org/10.1530/ERC-13-0515
L. Fabris, Y. Ceder, A.M. Chinnaiyan, G.W. Jenster, K.D. Sorensen, S. Tomlins, T. Visakorpi, G.A. Calin, The potential of microRNAs as prostate cancer biomarkers. Eur. Urol. 70(2), 312–322 (2016). https://doi.org/10.1016/j.eururo.2015.12.054
W. Qu, S.M. Ding, G. Cao, S.J. Wang, X.H. Zheng, G.H. Li, miR-132 mediates a metabolic shift in prostate cancer cells by targeting Glut1. FEBS Open Bio. 6(7), 735–741 (2016). https://doi.org/10.1002/2211-5463.12086
A. Singh, C. Happel, S.K. Manna, G. Acquaah-Mensah, J. Carrerero, S. Kumar, P. Nasipuri, K.W. Krausz, N. Wakabayashi, R. Dewi, L.G. Boros, F.J. Gonzalez, E. Gabrielson, K.K. Wong, G. Girnun, S. Biswal, Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J. Clin. Invest. 123(7), 2921–2934 (2013). https://doi.org/10.1172/JCI66353
J.W. Shih, L.Y. Wang, C.L. Hung, H.J. Kung, C.L. Hsieh, Non-coding RNAs in castration-resistant prostate cancer: regulation of AR signaling and cancer metabolism. Int. J. Mol. Sci. 16(12), 28943–28978 (2015). https://doi.org/10.3390/ijms161226138
M. Xin, Z. Qiao, J. Li, J. Liu, S. Song, X. Zhao, P. Miao, T. Tang, L. Wang, W. Liu, X. Yang, K. Dai, G. Huang, miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget 7(28), 44252–44265 (2016). https://doi.org/10.18632/oncotarget.10020
X. Li, Y.T. Chen, S. Josson, N.K. Mukhopadhyay, J. Kim, M.R. Freeman, W.C. Huang, MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One 8(8), e70987 (2013). https://doi.org/10.1371/journal.pone.0070987
W. Liu, A. Le, C. Hancock, A.N. Lane, C.V. Dang, T.W. Fan, J.M. Phang, Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl. Acad. Sci. 109(23), 8983–8988 (2012). https://doi.org/10.1073/pnas.1203244109
C.A. Lyssiotis, A.C. Kimmelman, Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 27(11), 863–875 (2017). https://doi.org/10.1016/j.tcb.2017.06.003
L. Marignol, K. Rivera-Figueroa, T. Lynch, D. Hollywood, Hypoxia, notch signalling, and prostate cancer. Nat. Rev. Urol. 10(7), 405–413 (2013). https://doi.org/10.1038/nrurol.2013.110
H. Geng, C. Xue, J. Mendonca, X.X. Sun, Q. Liu, P.N. Reardon, Y. Chen, K. Qian, V. Hua, A. Chen, F. Pan, J. Yuan, S. Dang, T.M. Beer, M.S. Dai, S.K. Kachhap, D.Z. Qian, Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. Nat. Commun. 9(1), 4972 (2018). https://doi.org/10.1038/s41467-018-07411-7
K. Zaugg, Y. Yao, P.T. Reilly, K. Kannan, R. Kiarash, J. Mason, P. Huang, S.K. Sawyer, B. Fuerth, B. Faubert, T. Kalliomaki, A. Elia, X. Luo, V. Nadeem, D. Bungard, S. Yalavarthi, J.D. Growney, A. Wakeham, Y. Moolani, J. Silvester, A.Y. Ten, W. Bakker, K. Tsuchihara, S.L. Berger, R.P. Hill, R.G. Jones, M. Tsao, M.O. Robinson, C.B. Thompson, G. Pan, T.W. Mak, Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25(10), 1041–1051 (2011). https://doi.org/10.1101/gad.1987211
Y. Jin, L. Wang, S. Qu, X. Sheng, A. Kristian, G.M. Maelandsmo, N. Pallmann, E. Yuca, I. Tekedereli, K. Gorgulu, N. Alpay, A. Sood, G. Lopez-Berestein, L. Fazli, P. Rennie, B. Risberg, H. Waehre, H.E. Danielsen, B. Ozpolat, F. Saatcioglu, STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol. Med. 7(3), 315–331 (2015). https://doi.org/10.15252/emmm.201404181
N.N. Tam, Y. Gao, Y.K. Leung, S.M. Ho, Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am. J. Pathol. 163(6), 2513–2522 (2003). https://doi.org/10.1016/S0002-9440(10)63606-1
D.A. Frohlich, M.T. McCabe, R.S. Arnold, M.L. Day, The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 27(31), 4353–4362 (2008). https://doi.org/10.1038/onc.2008.79
L. Khandrika, B. Kumar, S. Koul, P. Maroni, H.K. Koul, Oxidative stress in prostate cancer. Cancer Lett. 282(2), 125–136 (2009). https://doi.org/10.1016/j.canlet.2008.12.011
G.J. Samaranayake, C.I. Troccoli, M. Huynh, R.D.Z. Lyles, K. Kage, A. Win, V. Lakshmanan, D. Kwon, Y. Ban, S.X. Chen, E.R. Zarco, M. Jorda, K.L. Burnstein, P. Rai, Thioredoxin-1 protects against AR-induced redox vulnerability in castration-resistant prostate cancer. Nat. Commun. 8(1), 1204 (2017). https://doi.org/10.1038/s41467-017-01269-x
K. Li, Q. Zheng, X. Chen, Y. Wang, D. Wang, J. Wang, Isobavachalcone induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in human prostate cancer PC-3 cells. Oxid. Med. Cell. Longev. 2018, 1915828 (2018). https://doi.org/10.1155/2018/1915828
Y. Yan, L. Chang, H. Tian, L. Wang, Y. Zhang, T. Yang, G. Li, W. Hu, K. Shah, G. Chen, Y. Guo, 1-Pyrroline-5-carboxylate released by prostate cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS axis. J. Immunother. Cancer 6(1), 148 (2018). https://doi.org/10.1186/s40425-018-0466-z
K. Shiga, M. Hara, T. Nagasaki, T. Sato, H. Takahashi, H. Takeyama, Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 7(4), 2443–2458 (2015). https://doi.org/10.3390/cancers7040902
E. Giannoni, F. Bianchini, L. Masieri, S. Serni, E. Torre, L. Calorini, P. Chiarugi, Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70(17), 6945–6956 (2010). https://doi.org/10.1158/0008-5472.CAN-10-0785
F. Lopes-Coelho, S. Gouveia-Fernandes, J. Serpa, Metabolic cooperation between cancer and non-cancerous stromal cells is pivotal in cancer progression. Tumour Biol. 40(2), 1010428318756203 (2018). https://doi.org/10.1177/1010428318756203
T. Fiaschi, A. Marini, E. Giannoni, M.L. Taddei, P. Gandellini, A. De Donatis, M. Lanciotti, S. Serni, P. Cirri, P. Chiarugi, Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 72(19), 5130–5140 (2012). https://doi.org/10.1158/0008-5472.CAN-12-1949
P. Chiarugi, P. Paoli, P. Cirri, Tumor microenvironment and metabolism in prostate cancer. Semin. Oncol. 41(2), 267–280 (2014). https://doi.org/10.1053/j.seminoncol.2014.03.004
N. Pertega-Gomes, J.R. Vizcaino, J. Attig, S. Jurmeister, C. Lopes, F. Baltazar, A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 14, 352 (2014). https://doi.org/10.1186/1471-2407-14-352
A. Giatromanolaki, M.I. Koukourakis, A. Koutsopoulos, S. Mendrinos, E. Sivridis, The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol. Ther. 13(13), 1284–1289 (2012). https://doi.org/10.4161/cbt.21785
T. Fiaschi, E. Giannoni, M.L. Taddei, P. Cirri, A. Marini, G. Pintus, C. Nativi, B. Richichi, A. Scozzafava, F. Carta, E. Torre, C.T. Supuran, P. Chiarugi, Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 12(11), 1791–1801 (2013). https://doi.org/10.4161/cc.24902
A. Santi, A. Caselli, P. Paoli, D. Corti, G. Camici, G. Pieraccini, M.L. Taddei, S. Serni, P. Chiarugi, P. Cirri, The effects of CA IX catalysis products within tumor microenvironment. Cell Commun. Signal 11, 81 (2013). https://doi.org/10.1186/1478-811X-11-81
E.H. Cheteh, M. Augsten, H. Rundqvist, J. Bianchi, V. Sarne, L. Egevad, V.J. Bykov, A. Ostman, K.G. Wiman, Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis. 8(6), e2848 (2017). https://doi.org/10.1038/cddis.2017.225
Z.D. Nassar, A.T. Aref, D. Miladinovic, C.Y. Mah, G.V. Raj, A.J. Hoy, L.M. Butler, Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU Int. 121(Suppl 3), 9–21 (2018). https://doi.org/10.1111/bju.14173
J. Huang, A. Duran, M. Reina-Campos, T. Valencia, E.A. Castilla, T.D. Muller, M.H. Tschop, J. Moscat, M.T. Diaz-Meco, Adipocyte p62/SQSTM1 suppresses tumorigenesis through opposite regulations of metabolism in adipose tissue and tumor. Cancer Cell 33(4), 770–784.e776 (2018). https://doi.org/10.1016/j.ccell.2018.03.001
E. Gazi, J. Dwyer, N.P. Lockyer, P. Gardner, J.H. Shanks, J. Roulson, C.A. Hart, N.W. Clarke, M.D. Brown, Biomolecular profiling of metastatic prostate cancer cells in bone marrow tissue using FTIR microspectroscopy: a pilot study. Anal. Bioanal. Chem. 387(5), 1621–1631 (2007). https://doi.org/10.1007/s00216-006-1093-y
S. Balaban, Z.D. Nassar, A.Y. Zhang, E. Hosseini-Beheshti, M.M. Centenera, M. Schreuder, H.M. Lin, A. Aishah, B. Varney, F. Liu-Fu, L.S. Lee, S.R. Nagarajan, R.F. Shearer, R.A. Hardie, N.L. Raftopulos, M.S. Kakani, D.N. Saunders, J. Holst, L.G. Horvath, L.M. Butler, A.J. Hoy, Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Mol. Cancer Res. 17, 949 (2019). https://doi.org/10.1158/1541-7786.MCR-18-0347
Y. Tokuda, Y. Satoh, C. Fujiyama, S. Toda, H. Sugihara, Z. Masaki, Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int. 91(7), 716–720 (2003). https://doi.org/10.1046/j.1464-410X.2003.04218.x
J.D. Diedrich, E. Rajagurubandara, M.K. Herroon, G. Mahapatra, M. Huttemann, I. Podgorski, Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1alpha activation. Oncotarget 7(40), 64854–64877 (2016). https://doi.org/10.18632/oncotarget.11712
K. Fujita, P. Landis, B.K. McNeil, C.P. Pavlovich, Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J. Urol. 182(6), 2664–2669 (2009). https://doi.org/10.1016/j.juro.2009.08.044
M.G. Vander Heiden, Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10(9), 671–684 (2011). https://doi.org/10.1038/nrd3504
J. Kurhanewicz, D.B. Vigneron, K. Brindle, E.Y. Chekmenev, A. Comment, C.H. Cunningham, R.J. DeBerardinis, G.G. Green, M.O. Leach, S.S. Rajan, Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 13(2), 81–97 (2011). https://doi.org/10.1593/neo.101102
A.G. Wibmer, I.A. Burger, E. Sala, H. Hricak, W.A. Weber, H.A. Vargas, Molecular imaging of prostate cancer. Radiographics 36(1), 142–159 (2015). https://doi.org/10.1148/rg.2016150059
J.H. Ardenkjaer-Larsen, Hyperpolarized 13C magnetic resonance imaging-principles and applications, in Molecular Imaging: Principles and Practice, (People’s Medical Publishing House, Shelton, CT, 2009), pp. 377–388
P. Bhattacharya, B.D. Ross, R. Bünger, Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp. Biol. Med. 234(12), 1395–1416 (2009). https://doi.org/10.3181/0904-MR-135
K. Brindle, New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer 8(2), 94 (2008)
N. Zacharias, J. Lee, S. Ramachandran, S. Shanmugavelandy, J. McHenry, P. Dutta, S. Millward, S. Gammon, E. Efstathiou, P. Troncoso, D.E. Frigo, D. Piwnica-Worms, C.J. Logothetis, S.N. Maity, M.A. Titus, P. Bhattacharya, AR signaling in castration-resistant prostate cancer alters hyperpolarized pyruvate to lactate conversion and lactate levels in vivo. Mol. Imaging Biol. 21, 86 (2019). https://doi.org/10.1007/s11307-018-1199-6
P. Dutta, G.V. Martinez, R.J. Gillies, A new horizon of DNP technology: application to in-vivo 13 C magnetic resonance spectroscopy and imaging. Biophys. Re. 5(3), 271–281 (2013)
P. Dutta, A. Le, D.L. Vander Jagt, T. Tsukamoto, G.V. Martinez, C.V. Dang, R.J. Gillies, Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res. 73, 4190 (2013). https://doi.org/10.1158/0008-5472.CAN-13-0465
M.J. Albers, R. Bok, A.P. Chen, C.H. Cunningham, M.L. Zierhut, V.Y. Zhang, S.J. Kohler, J. Tropp, R.E. Hurd, Y.-F. Yen, Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 68(20), 8607–8615 (2008). https://doi.org/10.1158/0008-5472.CAN-08-0749
S.J. Nelson, J. Kurhanewicz, D.B. Vigneron, P.E. Larson, A.L. Harzstark, M. Ferrone, M. van Criekinge, J.W. Chang, R. Bok, I. Park, Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C] pyruvate. Sci. Transl. Med. 5(198), 198ra108 (2013). https://doi.org/10.1126/scitranslmed.3006070
R. Aggarwal, D.B. Vigneron, J. Kurhanewicz, Hyperpolarized 1-[13C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. Eur. Urol. 72(6), 1028–1029 (2017). https://doi.org/10.1016/j.eururo.2017.07.022
J.M. Lupo, A.P. Chen, M.L. Zierhut, R.A. Bok, C.H. Cunningham, J. Kurhanewicz, D.B. Vigneron, S.J. Nelson, Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. Magn. Reson. Imaging 28(2), 153–162 (2010). https://doi.org/10.1016/j.mri.2009.07.007
H.-Y. Chen, P.E. Larson, R.A. Bok, C. von Morze, R. Sriram, R.D. Santos, J.D. Santos, J.W. Gordon, N. Bahrami, M. Ferrone, Assessing prostate cancer aggressiveness with hyperpolarized dual-agent 3D dynamic imaging of metabolism and perfusion. Cancer Res. 77, 3207 (2017). https://doi.org/10.1158/0008-5472.CAN-16-2083
J.E. Lee, C.J. Diederich, R. Bok, R. Sriram, R.D. Santos, S.M. Noworolski, V.A. Salgaonkar, M.S. Adams, D.B. Vigneron, J. Kurhanewicz, Assessing high-intensity focused ultrasound treatment of prostate cancer with hyperpolarized 13C dual-agent imaging of metabolism and perfusion. NMR Biomed. 32, e3962 (2018). https://doi.org/10.1002/nbm.3962
S.S. Tee, I. Suster, S. Truong, S. Jeong, R. Eskandari, V. DiGialleonardo, J.A. Alvarez, H.N. Aldeborgh, K.R. Keshari, Targeted AKT inhibition in prostate cancer cells and spheroids reduces aerobic glycolysis and generation of hyperpolarized [1-(13)C] lactate. Mol. Cancer Res. 16(3), 453–460 (2018). https://doi.org/10.1158/1541-7786.MCR-17-0458
H. Dafni, P.E. Larson, S. Hu, H.A. Yoshihara, C.S. Ward, H.S. Venkatesh, C. Wang, X. Zhang, D.B. Vigneron, S.M. Ronen, Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 70, 7400 (2010). https://doi.org/10.1158/0008-5472.CAN-10-0883
K.R. Keshari, D.M. Wilson, M. Van Criekinge, R. Sriram, B.L. Koelsch, Z.J. Wang, H.F. VanBrocklin, D.M. Peehl, T. O’brien, D. Sampath, Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate 75(14), 1601–1609 (2015). https://doi.org/10.1002/pros.23036
B.T. Scroggins, M. Matsuo, A.O. White, K. Saito, J.P. Munasinghe, C. Sourbier, K. Yamamoto, V. Diaz, Y. Takakusagi, K. Ichikawa, Hyperpolarized [1-13C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect. Clin. Cancer Res. 24, 3137 (2018). https://doi.org/10.1158/1078-0432.CCR-17-1957
A. Lodi, S.M. Woods, S.M. Ronen, Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed. 26(3), 299–306 (2013). https://doi.org/10.1002/nbm.2848
C. Canapè, G. Catanzaro, E. Terreno, M. Karlsson, M.H. Lerche, P.R. Jensen, Probing treatment response of glutaminolytic prostate cancer cells to natural drugs with hyperpolarized [5-13C] glutamine. Magn. Reson. Med. 73(6), 2296–2305 (2015). https://doi.org/10.1002/mrm.25360
K.R. Keshari, V. Sai, Z.J. Wang, H.F. VanBrocklin, J. Kurhanewicz, D.M. Wilson, Hyperpolarized [1-13C] dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J. Nucl. Med. 54(6), 922–928 (2013). https://doi.org/10.2967/jnumed.112.115402
K.R. Keshari, D.M. Wilson, A.P. Chen, R. Bok, P.E. Larson, S. Hu, M.V. Criekinge, J.M. Macdonald, D.B. Vigneron, J. Kurhanewicz, Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J. Am. Chem. Soc. 131(48), 17591–17596 (2009). https://doi.org/10.1021/ja9049355
C.E. Christensen, M. Karlsson, J.R. Winther, P.R. Jensen, M.H. Lerche, Non-invasive in-cell determination of free cytosolic [NAD+]/[NADH] ratios using hyperpolarized glucose show large variations in metabolic phenotypes. J. Biol. Chem. 289(4), 2344–2352 (2014). https://doi.org/10.1074/jbc.M113.498626
D.M. Wilson, K.R. Keshari, P.E. Larson, A.P. Chen, S. Hu, M. Van Criekinge, R. Bok, S.J. Nelson, J.M. Macdonald, D.B. Vigneron, Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J. Magn. Reson. 205(1), 141–147 (2010). https://doi.org/10.1016/j.jmr.2010.04.012
S.S. Gambhir, Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2(9), 683 (2002)
T. Hara, N. Kosaka, H. Kishi, PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 39(6), 990–995 (1998)
J. Kotzerke, J. Prang, B. Neumaier, B. Volkmer, A. Guhlmann, K. Kleinschmidt, R. Hautmann, S.N. Reske, Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nucl. Med. 27(9), 1415–1419 (2000). https://doi.org/10.1007/s002590000309
M.A. Seltzer, S.A. Jahan, R. Sparks, D.B. Stout, N. Satyamurthy, M. Dahlbom, M.E. Phelps, J.R. Barrio, Radiation dose estimates in humans for 11C-acetate whole-body PET. J. Nucl. Med. 45(7), 1233–1236 (2004)
B. Savir-Baruch, L. Zanoni, D.M. Schuster, Imaging of prostate cancer using fluciclovine. Urol. Clin. North Am. 45(3), 489–502 (2018). https://doi.org/10.1016/j.ucl.2018.03.015
J. Cardinale, M. Schäfer, M. Benešová, U. Bauder-Wüst, K. Leotta, M. Eder, O.C. Neels, U. Haberkorn, F.L. Giesel, K. Kopka, Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J. Nucl. Med. 58(3), 425–431 (2017). https://doi.org/10.2967/jnumed.116.181768
R. Liu, J. Cao, X. Gao, J. Zhang, L. Wang, B. Wang, L. Guo, X. Hu, Z. Wang, Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumour Biol. 37(10), 14083–14088 (2016). https://doi.org/10.1007/s13277-016-5228-2
S. Halabi, E.J. Small, P.W. Kantoff, M.W. Kattan, E.B. Kaplan, N.A. Dawson, E.G. Levine, B.A. Blumenstein, N.J. Vogelzang, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21(7), 1232–1237 (2003). https://doi.org/10.1200/JCO.2003.06.100
H.I. Scher, G. Heller, A. Molina, G. Attard, D.C. Danila, X. Jia, W. Peng, S.K. Sandhu, D. Olmos, R. Riisnaes, R. McCormack, T. Burzykowski, T. Kheoh, M. Fleisher, M. Buyse, J.S. de Bono, Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 33(12), 1348–1355 (2015). https://doi.org/10.1200/JCO.2014.55.3487
O. Sartor, R.E. Coleman, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O’Sullivan, N.J. Vogelzang, O. Bruland, S. Kobina, S. Wilhelm, L. Xu, M. Shan, M.W. Kattan, C. Parker, An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann. Oncol. 28(5), 1090–1097 (2017). https://doi.org/10.1093/annonc/mdx044
L.R. Euceda, M.K. Andersen, M.-B. Tessem, S.A. Moestue, M.T. Grinde, T.F. Bathen, NMR-based prostate cancer metabolomics, in Prostate Cancer, (Springer, New York, NY, 2018), pp. 237–257
N.V. Reo, NMR-based metabolomics. Drug Chem. Toxicol. 25(4), 375–382 (2002). https://doi.org/10.1081/DCT-120014789
J.L. Markley, R. Brüschweiler, A.S. Edison, H.R. Eghbalnia, R. Powers, D. Raftery, D.S. Wishart, The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 43, 34–40 (2017). https://doi.org/10.1016/j.copbio.2016.08.001
H.K. Kim, Y.H. Choi, R. Verpoorte, NMR-based metabolomic analysis of plants. Nat. Protoc. 5(3), 536 (2010)
M.L. García-Martín, M. Adrados, M. Ortega, I. Fernández González, P. López-Larrubia, J. Viano, J. García-Segura, Quantitative 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn. Reson. Med. 65(2), 329–339 (2011). https://doi.org/10.1002/mrm.22631
N.J. Serkova, E.J. Gamito, R.H. Jones, C. O’donnell, J.L. Brown, S. Green, H. Sullivan, T. Hedlund, E.D. Crawford, The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68(6), 620–628 (2008). https://doi.org/10.1002/pros.20727
M.B. Tessem, M.G. Swanson, K.R. Keshari, M.J. Albers, D. Joun, Z.L. Tabatabai, J.P. Simko, K. Shinohara, S.J. Nelson, D.B. Vigneron, Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 60(3), 510–516 (2008). https://doi.org/10.1002/mrm.21694
D. Kumar, A. Gupta, A. Mandhani, S.N. Sankhwar, Metabolomics-derived prostate cancer biomarkers: fact or fiction? J. Proteome Res. 14(3), 1455–1464 (2015). https://doi.org/10.1021/pr5011108
M.G. Swanson, K.R. Keshari, Z.L. Tabatabai, J.P. Simko, K. Shinohara, P.R. Carroll, A.S. Zektzer, J. Kurhanewicz, Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn. Reson. Med. 60(1), 33–40 (2008). https://doi.org/10.1002/mrm.21647
R.A. Komoroski, J.C. Holder, A.A. Pappas, A.E. Finkbeiner, 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magn. Reson. Med. 65(4), 911–913 (2011). https://doi.org/10.1002/mrm.22677
G. Zadra, M. Loda, Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities. Cold Spring Harb. Perspect. Med. 8(10), a030569 (2018). https://doi.org/10.1101/cshperspect.a030569
T. Cajka, O. Fiehn, Toward merging untargeted and targeted methods in mass spectrometry-based metabolomics and lipidomics. Anal. Chem. 88(1), 524–545 (2015). https://doi.org/10.1021/acs.analchem.5b04491
D.S. Wishart, Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 15(7), 473 (2016)
Y.-F. Xu, W. Lu, J.D. Rabinowitz, Avoiding misannotation of in-source fragmentation products as cellular metabolites in liquid chromatography–mass spectrometry-based metabolomics. Anal. Chem. 87(4), 2273–2281 (2015). https://doi.org/10.1021/ac504118y
N.R. Kitteringham, R.E. Jenkins, C.S. Lane, V.L. Elliott, B.K. Park, Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B 877(13), 1229–1239 (2009)
R. Thapar, M.A. Titus, Recent advances in metabolic profiling and imaging of prostate cancer. Curr. Metab. 2(1), 53–69 (2014)
B. Guo, B. Chen, A. Liu, W. Zhu, S. Yao, Liquid chromatography-mass spectrometric multiple reaction monitoring-based strategies for expanding targeted profiling towards quantitative metabolomics. Curr. Drug Metab. 13(9), 1226–1243 (2012)
G. Zadra, C. Photopoulos, M. Loda, The fat side of prostate cancer. Biochim. Biophys. Acta 1831(10), 1518–1532 (2013). https://doi.org/10.1016/j.bbalip.2013.03.010
J. Whitburn, C.M. Edwards, P. Sooriakumaran, Metformin and prostate cancer: a new role for an old drug. Curr. Urol. Rep. 18, 1–7 (2017). https://doi.org/10.1007/s11934-017-0693-8
K.A. Richards, L. Ji, V.L. Cryns, T.M. Downs, E.J. Abel, D.F. Jarrard, Metformin use is associated with improved survival for patients with advanced prostate cancer on androgen deprivation therapy. J. Urol. 200, 1256–1263 (2018). https://doi.org/10.1016/j.juro.2018.06.031
E.H. Allott, M.R. Abern, L. Gerber, C.J. Keto, W.J. Aronson, M.K. Terris, C.J. Kane, C.L. Amling, M.R. Cooperberg, P.G. Moorman, S.J. Freedland, Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 16(4), 391–397 (2013). https://doi.org/10.1038/pcan.2013.48
M. Rieken, E. Xylinas, L. Kluth, J.J. Crivelli, J. Chrystal, T. Faison, Y. Lotan, P.I. Karakiewicz, H. Fajkovic, M. Babjuk, A. Kautzky-Willer, A. Bachmann, D.S. Scherr, S.F. Shariat, Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 112(8), 1105–1112 (2013). https://doi.org/10.1111/bju.12448
S.Y. Wang, C.S. Chuang, C.H. Muo, S.T. Tu, M.C. Lin, F.C. Sung, C.H. Kao, Metformin and the incidence of cancer in patients with diabetes: a nested case-control study. Diabetes Care 36(9), e155–e156 (2013). https://doi.org/10.2337/dc13-0708
D. Soranna, L. Scotti, A. Zambon, C. Bosetti, G. Grassi, A. Catapano, C. La Vecchia, G. Mancia, G. Corrao, Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17(6), 813–822 (2012). https://doi.org/10.1634/theoncologist.2011-0462
L. Azoulay, S. Dell’Aniello, B. Gagnon, M. Pollak, S. Suissa, Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomarkers Prev. 20(2), 337–344 (2011). https://doi.org/10.1158/1055-9965.EPI-10-0940
L. Bensimon, H. Yin, S. Suissa, M.N. Pollak, L. Azoulay, The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol. Biomarkers Prev. 23(10), 2111–2118 (2014). https://doi.org/10.1158/1055-9965.EPI-14-0056
C.J. Currie, C.D. Poole, E.A. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9), 1766–1777 (2009). https://doi.org/10.1007/s00125-009-1440-6
D. Kaushik, R.J. Karnes, M.S. Eisenberg, L.J. Rangel, R.E. Carlson, E.J. Bergstralh, Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol. Oncol. 32(1), 43.e41–43.e47 (2014). https://doi.org/10.1016/j.urolonc.2013.05.005
D. Margel, D. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkarni, P.C. Austin, N. Fleshner, Association between metformin use and risk of prostate cancer and its grade. J. Natl. Cancer Inst. 105(15), 1123–1131 (2013). https://doi.org/10.1093/jnci/djt170
T. Patel, G. Hruby, K. Badani, C. Abate-Shen, J.M. McKiernan, Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76(5), 1240–1244 (2010). https://doi.org/10.1016/j.urology.2010.03.059
K.K. Tsilidis, D. Capothanassi, N.E. Allen, E.C. Rizos, D.S. Lopez, K. van Veldhoven, C. Sacerdote, D. Ashby, P. Vineis, I. Tzoulaki, J.P. Ioannidis, Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37(9), 2522–2532 (2014). https://doi.org/10.2337/dc14-0584
T. Feng, X. Sun, L.E. Howard, A.C. Vidal, A.R. Gaines, D.M. Moreira, R. Castro-Santamaria, G.L. Andriole, S.J. Freedland, Metformin use and risk of prostate cancer: results from the REDUCE study. Cancer Prev. Res. (Phila.) 8(11), 1055–1060 (2015). https://doi.org/10.1158/1940-6207.CAPR-15-0141
A.M. Joshua, V.E. Zannella, M.R. Downes, B. Bowes, K. Hersey, M. Koritzinsky, M. Schwab, U. Hofmann, A. Evans, T. van der Kwast, J. Trachtenberg, A. Finelli, N. Fleshner, J. Sweet, M. Pollak, A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 17(3), 252–258 (2014). https://doi.org/10.1038/pcan.2014.20
Medicine UNLo, ClinicalTrials.gov (2015). https://clinicaltrials.gov/ct2/show/NCT01433913
A. Vancura, P. Bu, M. Bhagwat, J. Zeng, I. Vancurova, Metformin as an anticancer agent. Trends Pharmacol. Sci. 39, 867–878 (2018). https://doi.org/10.1016/j.tips.2018.07.006
X. Liu, I.L. Romero, L.M. Litchfield, E. Lengyel, J.W. Locasale, Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 24, 728–739 (2016). https://doi.org/10.1016/j.cmet.2016.09.005
V. Zingales, A. Distefano, M. Raffaele, A. Zanghi, I. Barbagallo, L. Vanella, Metformin: a bridge between diabetes and prostate cancer. Front. Oncol. 7, 1–7 (2017). https://doi.org/10.3389/fonc.2017.00243
T.M. Ashton, W.G. McKenna, L.A. Kunz-Schughart, G.S. Higgins, Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24, 2482–2490 (2018). https://doi.org/10.1158/1078-0432.CCR-17-3070
L.B. Sullivan, D.Y. Gui, A.M. Hosios, L.N. Bush, E. Freinkman, M.G. Vander Heiden, Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162(3), 552–563 (2015). https://doi.org/10.1016/j.cell.2015.07.017
K. Birsoy, T. Wang, W.W. Chen, E. Freinkman, M. Abu-Remaileh, D.M. Sabatini, An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162(3), 540–551 (2015). https://doi.org/10.1016/j.cell.2015.07.016
R.J. DeBerardinis, N.S. Chandel, Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016). https://doi.org/10.1126/sciadv.1600200
J.R. Molina, Y. Sun, M. Protopopova, S. Gera, M. Bandi, C. Bristow, T. McAfoos, P. Morlacchi, J. Ackroyd, A.-nA. Agip, G. Al-Atrash, J. Asara, J. Bardenhagen, C.C. Carrillo, C. Carroll, E. Chang, S. Ciurea, J.B. Cross, B. Czako, A. Deem, N. Daver, J.F. de Groot, J.-w. Dong, N. Feng, G. Gao, J. Gay, M.G. Do, J. Greer, V. Giuliani, J. Han, L. Han, V.K. Henry, J. Hirst, S. Huang, Y. Jiang, Z. Kang, T. Khor, S. Konoplev, Y.-h. Lin, G. Liu, A. Lodi, T. Lofton, H. Ma, M. Mahendra, P. Matre, R. Mullinax, M. Peoples, A. Petrocchi, J. Rodriguez-Canale, R. Serreli, T. Shi, M. Smith, Y. Tabe, J. Theroff, S. Tiziani, Q. Xu, Q. Zhang, F. Muller, R.A. DePinho, C. Toniatti, G.F. Draetta, T.P. Heffernan, M. Konopleva, P. Jones, M.E. Di Francesco, J.R. Marszalek, An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018). https://doi.org/10.1038/s41591-018-0052-4
D.A. Bader, S.M. Hartig, V. Putluri, C. Foley, M.P. Hamilton, E.A. Smith, P.K. Saha, A. Panigrahi, C. Walker, L. Zong, H. Martini-Stoica, R. Chen, K. Rajapakshe, C. Coarfa, A. Sreekumar, N. Mitsiades, J.A. Bankson, M.M. Ittmann, B.W. O’Malley, N. Putluri, S.E. McGuire, Mitochondrial pyruvate import is a metabolic vulnerability in AR-driven prostate cancer. Nat. Metab. 1, 70–85 (2019). https://doi.org/10.1038/s42255-018-0002-y
Q. Wang, R.A. Hardie, A.J. Hoy, M. Van Geldermalsen, D. Gao, L. Fazli, M.C. Sadowski, S. Balaban, M. Schreuder, R. Nagarajah, J.J.L. Wong, C. Metierre, N. Pinello, N.J. Otte, M.L. Lehman, M. Gleave, C.C. Nelson, C.G. Bailey, W. Ritchie, J.E. Rasko, J. Holst, Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J. Pathol. 236, 278–289 (2015). https://doi.org/10.1002/path.4518
C. Yang, B. Ko, C.T. Hensley, L. Jiang, A.T. Wasti, J. Kim, J. Sudderth, M.A. Calvaruso, L. Lumata, M. Mitsche, J. Rutter, M.E. Merritt, R.J. DeBerardinis, Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 56, 414–424 (2014). https://doi.org/10.1016/j.molcel.2014.09.025
C. Adams, R.C. Richmond, D.L. Santos Ferreira, W. Spiller, V.Y. Tan, J. Zheng, P. Wurtz, J.L. Donovan, F.C. Hamdy, D.E. Neal, J.A. Lane, G. Davey Smith, C.L. Relton, R.A. Eeles, B.E. Henderson, C.A. Haiman, Z. Kote-Jarai, F.R. Schumacher, A. Amin Al Olama, S. Benlloch, K. Muir, S.I. Berndt, D.V. Conti, F. Wiklund, S.J. Chanock, S.M. Gapstur, V.L. Stevens, C.M. Tangen, J. Batra, J.A. Clements, H. Gronberg, N. Pashayan, J. Schleutker, D. Albanes, A. Wolk, C.M.L. West, L.A. Mucci, G. Cancel-Tassin, S. Koutros, K.D. Sorensen, L. Maehle, R.C. Travis, R. Hamilton, S.A. Ingles, B.S. Rosenstein, Y.J. Lu, G.G. Giles, A.S. Kibel, A. Vega, M. Kogevinas, K.L. Penney, J.Y. Park, J.L. Stanford, C. Cybulski, B.G. Nordestgaard, H. Brenner, C. Maier, J. Kim, E.M. John, M.R. Teixeira, S.L. Neuhausen, K. DeRuyck, A. Razack, L.F. Newcomb, D. Lessel, R.P. Kaneva, N. Usmani, F. Claessens, P. Townsend, M. Gago Dominguez, M.J. Roobol, F. Menegaux, K.T. Khaw, L.A. Cannon-Albright, H. Pandha, S.N. Thibodeau, R.M. Martin, Circulating metabolic biomarkers of screen-detected prostate cancer in the ProtecT study. Cancer Epidemiol. Biomarkers Prev. 28, 208 (2019). https://doi.org/10.1158/1055-9965.EPI-18-0079
J. Huang, A.M. Mondul, S.J. Weinstein, S. Koutros, A. Derkach, E. Karoly, J.N. Sampson, S.C. Moore, S.I. Berndt, D. Albanes, Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Br. J. Cancer 115(9), 1087–1095 (2016). https://doi.org/10.1038/bjc.2016.305
A.M. Mondul, S.C. Moore, S.J. Weinstein, E.D. Karoly, J.N. Sampson, D. Albanes, Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int. J. Cancer 137(9), 2124–2132 (2015). https://doi.org/10.1002/ijc.29576
A.M. Mondul, S.C. Moore, S.J. Weinstein, S. Mannisto, J.N. Sampson, D. Albanes, 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 10(5), 1036–1041 (2014). https://doi.org/10.1007/s11306-014-0643-0
J.R. Mayers, M.G. Vander Heiden, Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem. Sci. 40(3), 130–140 (2015). https://doi.org/10.1016/j.tibs.2015.01.004
S.M. Davidson, T. Papagiannakopoulos, B.A. Olenchock, J.E. Heyman, M.A. Keibler, A. Luengo, M.R. Bauer, A.K. Jha, J.P. O’Brien, K.A. Pierce, D.Y. Gui, L.B. Sullivan, T.M. Wasylenko, L. Subbaraj, C.R. Chin, G. Stephanopolous, B.T. Mott, T. Jacks, C.B. Clish, M.G. Vander Heiden, Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23(3), 517–528 (2016). https://doi.org/10.1016/j.cmet.2016.01.007
J.A. Reisz, A. D’Alessandro, Measurement of metabolic fluxes using stable isotope tracers in whole animals and human patients. Curr. Opin. Clin. Nutr. Metab. Care 20(5), 366–374 (2017). https://doi.org/10.1097/MCO.0000000000000393
B. Faubert, K.Y. Li, L. Cai, C.T. Hensley, J. Kim, L.G. Zacharias, C. Yang, Q.N. Do, S. Doucette, D. Burguete, H. Li, G. Huet, Q. Yuan, T. Wigal, Y. Butt, M. Ni, J. Torrealba, D. Oliver, R.E. Lenkinski, C.R. Malloy, J.W. Wachsmann, J.D. Young, K. Kernstine, R.J. DeBerardinis, Lactate metabolism in human lung tumors. Cell 171(2), 358–371.e359 (2017). https://doi.org/10.1016/j.cell.2017.09.019
C.T. Hensley, B. Faubert, Q. Yuan, N. Lev-Cohain, E. Jin, J. Kim, L. Jiang, B. Ko, R. Skelton, L. Loudat, M. Wodzak, C. Klimko, E. McMillan, Y. Butt, M. Ni, D. Oliver, J. Torrealba, C.R. Malloy, K. Kernstine, R.E. Lenkinski, R.J. DeBerardinis, Metabolic heterogeneity in human lung tumors. Cell 164(4), 681–694 (2016). https://doi.org/10.1016/j.cell.2015.12.034
A.H. Davies, H. Beltran, A. Zoubeidi, Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15(5), 271–286 (2018). https://doi.org/10.1038/nrurol.2018.22
Acknowledgements
We thank Kelly Kage (UT MD Anderson Cancer Center) for assistance with the figures. This work was supported by grants from the National Institutes of Health (R01CA184208 to D.E.F.; P50CA094056, U54CA151668 and R21CA185536 to P.B.), American Cancer Society (RSG-16-084-01-TBE to D.E.F.), an Institutional Research Grant (to P.B.), startup grants from the University of Texas MD Anderson Cancer Center (to P.B. and D.E.F.), a grant from the Gulf Coast Consortium (to P.B.) and generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program (to D.E.F.) and Koch Foundation Genitourinary Medical Oncology Funds (to P.B.). This work was also supported by an Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship (to C.L.), an American Legion Auxiliary Fellowship (to D.A.), a CPRIT Research Training Grant Award (RP170067 to T.C.S.) and a GCC/Keck Center CCBTP postdoctoral fellowship (CPRIT RP170593 to S.P.). M.T. also acknowledges support from the Neubauer Family Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lin, C. et al. (2019). Prostate Cancer Energetics and Biosynthesis. In: Dehm, S., Tindall, D. (eds) Prostate Cancer. Advances in Experimental Medicine and Biology, vol 1210. Springer, Cham. https://doi.org/10.1007/978-3-030-32656-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-32656-2_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32655-5
Online ISBN: 978-3-030-32656-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)